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Abstract
Multiple sclerosis (MS) is the most common neurological disease in young Canadians,
yet its etiology remains obscure. Two possibly related findings in MS are brain iron
deposition and the presence of small veins in white matter lesions. This thesis concerns
the development and application of 3 Tesla magnetic resonance imaging tools to image
iron and veins in early multiple sclerosis.
To facilitate measurements of iron concentration as well as production of cerebral
venograms, we first optimized multi-echo susceptibility weighted imaging (SWI), using
numerical simulations and input from physicians. We validated measurements of R2*, an
MRI parameter that scales linearly with iron concentration.
Subsequently, we proposed quantification of the caliber of the internal jugular veins
(IJVs) from magnetic resonance venograms. IJVs are implicated in the chronic
cerebrospinal venous insufficiency model of MS, an increasingly disputed theory that
attributes iron deposition in MS to venous abnormalities. We report that the coefficient of
variation of measurements of average cross-sectional area of the IJVs is on the order of
7%.
We performed quantitative investigations of iron concentration in a cohort of patients at
risk of MS diagnosis, compared to healthy controls. We report increased R2* (putative
iron) in deep as well as cortical grey matter in patients. We subsequently measured IJV
area, finding a trend for reduced total IJV caliber in patients; however, we found no
correlation between R2* changes and IJV area.
We investigated the ability of multi-echo SWI to detect central veins within white matter
hyperintensities (WMHs). We found that patients who converted from clinically isolated
syndrome (CIS) to MS had a larger fraction of lesions with central veins compared to
patients with non-converted CIS and healthy controls. Moreover, all patients who
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received a diagnosis of MS within the study window had >40% lesions with central veins
at their CIS baselines, suggesting there may be predictive value in this biomarker.
The subjects from these last two studies represent a subset of our cohort in an ongoing
longitudinal study. Using methodology described herein, we are equipped to further
investigate different biomarkers of disease to better understand early pathology in MS.

Keywords
Multiple sclerosis, MRI, brain iron, clinically isolated syndromes, susceptibility weighted
imaging, cervical veins
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Introduction

This thesis is concerned with the development and application of magnetic resonance
imaging (MRI) techniques for the study of pathological components in early multiple
sclerosis (MS) including iron accumulation and a role for veins. This chapter will provide
the background and rationale for imaging studies described in this thesis. First, a
summary of natural history, imaging, and pathology of MS is presented. Second, relevant
details of MRI techniques employed herein are provided, culminating in a description of
susceptibility weighted imaging and !!∗ relaxometry. Third, in order to address a recent
theory of MS pathogenesis, normal drainage of blood from the central nervous system
(CNS) and chronic cerebrospinal venous insufficiency (CCSVI) are discussed. Finally,
this chapter concludes with a brief overview of subsequent chapters of this thesis.

1.1
1.1.1

Multiple Sclerosis

Natural history

Multiple sclerosis (MS) is the most prevalent neurological disease that affects young
adults in Canada, with roughly 55,000 to 75,000 individuals affected1. Prevalence varies
by region, but MS affects approximately 88 per 100,000 individuals in London, Ontario,
and 85 per 100,000 in surrounding Middlesex County2. MS affects more than twice as
many women as it does men3, an unexplained bias. Curiously, this ratio has been steadily
increasing since the early 20th century, also for unknown reasons; this is potentially
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related to environmental or gene-environment contributions. MS affects primarily
Caucasians of Northern European ancestry4.
In 85% of individuals with MS, disease onset is marked by a clinically isolated syndrome
(CIS), typically affecting the optic nerves, spine, or brainstem5. In brief, a CIS is an acute
or sub-acute episode of neurological disturbance due to a single white matter lesion; this
may be the first evidence of MS, although further studies are required to confirm or
exclude MS as the diagnosis. A brief summary of common differential diagnoses for MS
is provided below. In general, 30-70% of patients presenting with a CIS will eventually
be diagnosed with clinically definite MS (CDMS)6. In 80-90% of patients with MS,
disease course is initially marked with relapsing/remitting symptoms – so called relapsing
remitting MS (RRMS)4. In these patients, disease onset is usually in the third or fourth
decade of life. The interval between relapses is random, but early in the disease course
relapses typically occur once a year, decreasing in frequency with time. Eventually, the
disease is marked by a steady worsening of symptoms that occurs independently of
relapses. At this stage, the disease is called secondary progressive MS (SPMS)7. In one
study, median time to SPMS from diagnosis of RRMS was 21.4 years, occurring at a
median age of 53.7 years8.
In the remaining 10-20% of patients, the disease is characterized by steady progression of
symptoms in the absence of relapses from onset9. This disease is termed primary
progressive MS (PPMS) and generally carries the worst prognosis10. Although
immunomodulatory drugs can reduce the frequency and severity of relapses in RRMS,
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they are of no benefit for progressive symptoms. Onset of PPMS is generally during the
fourth or fifth decade.
In about one quarter of patients, MS never affects activities of daily living; alternatively,
15% of patients become severely disabled within a short time4.

1.1.2

Magnetic resonance imaging for MS

MRI has an intimate role in the diagnosis of MS, where it is used to establish that the
disease shows dissemination in space (DIS) as well as dissemination in time (DIT)11.
Moreover, MRI can be used to evaluate and exclude many typical differential diagnoses
in patients with MS-like presentations12. Current diagnostic criteria rely on MRI to
visualize white matter lesions in different regions of the brain and spinal cord. Based on
MRI findings, DIS can be demonstrated with one or more T2 lesions (i.e. a lesion with
hyperintense signal on T2-weighted images) in at least two of four white matter areas:
periventricular, juxtacortical, infratentorial, and spinal cord (however, symptomatic
brainstem and cord lesions are excluded from lesion counts). DIT can be demonstrated by
a new T2 or contrast-enhancing lesion (i.e. a lesion with hyperintense signal on T1weighted images following intravenous injection of a contrast agent) on a follow-up
MRI, or the simultaneous presence of asymptomatic contrast-enhancing and nonenhancing lesions at any time.
As noted above, the exclusion of other neurological disorders is an essential step when
considering an MS diagnosis12. In general, there is a long list of diseases that share
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radiological similarities with MS largely owing to the relatively limited specificity of
abnormalities visualized by clinical MRI images (namely, hyperintense foci on T2
weighted images). How MRI may be used to vet a list of possible diagnoses is beyond the
scope of this thesis (this information is available elsewhere13). Inflammatory
demyelinating diseases that may challenge the differential diagnosis include atypical
presentations of MS (acute presentations, Balo’s sclerosis, tumefactive disease), acute
disseminate encephalomyelitis, and neuromyelitis optica. The extensive list of diseases
with similar MRI findings as MS despite distinct underlying pathologies includes
vascular, metabolic, and neurodegenerative disorders. Additionally, many rheumatic
diseases (Lupus, Sjögren’s syndrome, Behçet’s syndrome) may have neurological
presentations14 and MRI findings which can be challenging to differentiate from MS.
MRI-based criteria for MS diagnosis have been proposed and revised several times since
200111,15-17, with a trend towards becoming simpler to use and less reliant on the use of a
contrast agent. In addition to being an invasive and potentially uncomfortable procedure,
intravenous administration of contrast agent holds a small risk of severe allergic
reaction18. Revisions to diagnostic criteria have maintained a relatively high specificity to
CDMS of approximately 90%, but sensitivity remains modest, at best. One study
estimated sensitivity of the new criteria to CDMS to be at 72%19 (in other words, there
was a tendency to under-diagnose/miss cases of MS). In that study, diagnosis with
CDMS took a median of 8 months from clinical presentation, and in some individuals
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diagnosis may take years20. Clearly, the ideal criteria would facilitate high specificity,
high sensitivity diagnosis to be made at first presentation.
The current diagnostic criteria do not indicate what MRI field strength is appropriate for
these studies11; however, the criteria are generally based on the most common clinical
strength of 1.5 T. As higher field strength scanners become more prevalent, extension of
these criteria to different field strengths is imperative. It is clear from several studies that
inflammatory white matter lesions are increasingly visible at higher field. One estimate
suggests a 40% increase in the number of lesions detected at 3 T compared to 1.5 T21,
although it is unclear how this will affect diagnosis and prognosis for patients22,23.
MRI contrasts (meaning image contrasts achieved by different acquisition methods) that
are typically used in the clinic (generally at 1.5 T) do not visualize all damage to
neurological tissues in MS, and therefore do not provide a complete assessment of
disease burden. Non-conventional MR techniques (i.e. not yet used in a clinical setting)
allow evaluation of diffuse changes to normal appearing white matter24, lesions in grey
matter25, as well as iron accumulation26. It remains to be seen how these novel techniques
can be used to complement existing diagnostic criteria. Ultimately, advanced MRI
methods may provide better assessment of risk of conversion from CIS to MS27.

1.1.3

Pathology

MS is generally held to be a chronic autoimmune disorder of the CNS28,29. Manifestation
of the disease arises from interactions between inherited predisposition30 and
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environmental factors31. The most familiar pathology of MS, and that from which the
disease takes its name, is the demyelinating plaque or lesion of the white matter.
Characteristically positioned along small veins32, white matter plaques in MS are by
definition disseminated throughout the CNS.
Early in the lifetime of a lesion (i.e. when the lesion is referred to as an active plaque),
adhesion molecules on the endothelial surface of a post-capillary venule interact with
mononuclear cells (T cells, B cells, and macrophages) to facilitate the invasion of these
cells from the circulation into the CNS parenchyma through the blood brain barrier33.
Activated autoreactive T cells (i.e. that recognize one or more neuro self-antigens)
produce cytokines that mediate the inflammatory environment and may cause direct
injury to oligodendrocytes and myelin. Activated B cells also secrete cytokines and
produce demyelinating antibodies34. Macrophages may adopt a pro-inflammatory
phenotype: this appears to be associated with, and potentially induced by, high iron
uptake35. Alternatively, macrophages may adopt an anti-inflammatory phenotype
involving phagocytosis/clearance of myelin debris, which is necessary for remyelination
of denuded axons36. Additionally, active plaques are characterized by edema, apoptosis of
oligodendrocytes37, and the presence of reactive microglia38. There is considerable
heterogeneity in the pathology of white matter lesions as well: Lucchinetti et al.39 have
characterized four fundamentally different types of demyelination from large pathology
studies. Type I lesions demonstrate primarily T cell mediated demyelination. Type II
lesions also show T cell mediated damage, in addition to antibody-mediated changes.
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Both Type III and IV lesions show extensive damage to and loss of oligodendrocytes,
with Type IV lesions being found exclusively in PPMS.
Alternatively, chronic plaques in MS are distinguished by diminished/absent
inflammation40, relative lack of reactive glia, astrocytic scarring41, and myelin-laden
macrophages typically found at the rim of the lesion35. Remyelination is the reparative
process by which denuded axons are invested with new myelin sheaths. Remyelination
may be present in chronic lesions, but is typically only located to the outer rim of the
lesion42. Axonal transection and degeneration occur not only within the active lesion, but
also in the chronic lesion43 where the lack of trophic factors provided by myelin is
postulated to be responsible for axonal loss44.
It has become increasingly apparent that damage to neurological tissues in multiple
sclerosis extends beyond white matter. Demyelinating lesions are found in as much as 2530% of the grey matter, as opposed to 5-15% of white matter45. Atrophy has been
reported in both grey and white matter of MS patients, although grey matter atrophy
appears to correlate better with disease disability than measures of white matter46,47. Over
the past three decades, iron accumulation has been consistently reported in regions of the
brain affected by multiple sclerosis26, although its role is, as of yet, unclear. Moreover,
the close association of MS plaques and cerebral veins, noted from the earliest
descriptions of the disease32, remains incompletely explained and may be central to the
evolution of the plaque and the disease. These two findings – increased iron and
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association of pathology with cerebral veins – form the central motivation for this thesis
and will be discussed respectively below.

1.1.4

Iron in MS

Neurological tissues normally contain high concentrations of iron48. In white matter,
many components of the enzymatic machinery required for myelin synthesis and
maintenance require iron as a catalytic center. As such, the normally high levels of intracellular iron, generally stored in ferritin, are unsurprising. The oft-cited calorimetry study
of Hallgren and Sourander established that iron accumulates with age in cortical grey
matter and, at a greater rate, in deep grey matter structures in the normal brain49.
Dysregulation of iron homeostasis is a feature of several neurological conditions,
including Alzheimer50 and Parkinson’s51 diseases. Starting in the early 1980’s, a series of
histological studies suggested abnormal iron accumulation might occur in MS as well.
The study of Craelius et al. demonstrated the presence of iron reactivity surrounding MS
lesions and associated with nearby blood vessels52. Adams found evidence of increased
iron storage protein haemosiderin within the vein wall in MS lesions consistent with
previous microhemorrhage, and concluded that the cerebral vein wall in MS is subject to
extensive inflammatory damage53. Using a highly sensitive iron-staining technique,
Levine et al. demonstrated increased iron in reactive microglia, ameboid microglia,
macrophages, oligodendrocytes, and myelin within MS lesions50, which may suggest an
underlying iron metabolism disorder. The specific mechanism of iron accumulation in
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MS remains unknown. Serum levels of transferrin receptor (whose ligand is the ironbinding protein transferrin) are increased in MS patients54; iron in this form can be
transported across the blood brain barrier and released as elemental iron into the brain
interstitial fluid55. Alterations in brain iron levels may be a downstream effect of an
autoimmune response56; alternatively, iron may provoke inflammation directly35. In
either case, iron might serve as a source of oxidative stress57 (to which lipid-rich tissue,
such as myelin, is especially susceptible58), thus increasing tissue damage.
In passing, it is interesting that iron and its homeostasis are major factors involved in
inflammation in settings outside the CNS, where iron levels correlate with markers of
chronic inflammation59. Notably, in rheumatic diseases, ferritin levels predict disease
activity60, and removal of iron is associated with improved clinical outcomes61.
Owing to its high sensitivity to iron, MRI was utilized in several early studies of iron in
MS, especially with respect to deep grey matter iron where it continues to be a preferred
tool for such work. Drayer was the first to interpret decreased signal intensity on T2weighted images of MS patients in several deep grey matter structures as increased iron62.
Increased iron in basal ganglia structures has since been confirmed by numerous MRI
studies using T2 hypointensity63, relaxation rate64, phase65, and magnetic field
correlation66. The significance of deep grey matter iron is unknown in MS, although it
may cause cellular damage57 and thus contribute to clinical disability67.
As these studies tend to have been performed cross-sectionally in time on patients with
CDMS, they have not established (i) at what stage of the disease iron accumulation
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occurs (both within lesions and in deep grey matter), or (ii) whether iron is a primarily a
cause or consequence of pathology. At least two recent studies have interrogated iron
levels in deep grey matter or patients with CIS (a subset of who presumably will be
diagnosed with MS), working under the hypothesis that, if iron is a cause of MS, it
should be present at first clinical presentations. However, these studies have found
contradictory results, with one reporting iron is increased in patients with a CIS68, and the
other finding no such difference67. These contrasting results are likely related to
methodological differences in iron concentration measurements or age of CIS patients as
described more thoroughly in the Discussion in Chapter 4.

1.1.5

Small veins in MS

An anatomical association of MS lesions and small veins has been known for over a
century, although pathological consequences of this association remain unclear. In 1868,
Charcot reported that sclerotic plaques of MS were typically positioned along small
veins, as determined from analyses of autopsy specimens32. In 1916, Dawson described
lesions of MS that spread along prominent periventricular veins69. Today, such lesions
are known to be very typical for MS and are known as Dawson’s fingers70. In 1963, Fog
reported on 30 MS plaques from cadaver brains, stating such lesions typically followed
the course of small veins71.
Functionally, the central venule within a lesion is directly involved in the lesion’s
pathogenesis. Breakdown of the blood brain barrier precedes symptoms and other MRI
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signs of a new lesion72. In the acute lesion40,53, perivenous inflammation and cuffing of
the vascular wall are present and are associated with infiltration of mononuclear cells,
demyelination, and axonal damage. In chronic lesions, evidence of long-standing
vascular injury includes thickening or hyalinization of the vein wall, in addition to signs
of previous microhemorrhage73.
More recently, MRI has been used to demonstrate the presence of a central venule in
many MS plaques72,74. Recent studies have proposed that the presence of a central vein
within white matter T2 hyperintensities may be specific to MS, and this specificity could
be exploited for the benefit of diagnosis75,76.
Over the past century, various theories have been put forth that attribute the origins of
MS pathology to venous occlusion or reflux in (relatively large) intra- or extra-cranial
vessels resulting in microhemorrhage including pathological iron deposition upstream
(putatively at the position of a subsequent lesion)77. In such a model, iron is a driving
factor for inflammation and subsequent antigen presentation. While these theories might
initially appeal to logic inasmuch as an association of demyelinating foci with small veins
and iron is known, they have been insufficient with respective to objective evidence or
scientific support. However, evidence is more supportive of increased iron in MS as
secondary to an autoimmune response that is associated with (1) increased transport of
iron into the brain from circulation54, and/or, (2) irregular metabolism of iron56. In these
cases, a subsequent toxic57 or pro-inflammatory role35 for increased iron cannot yet be
ruled out.
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1.2

Gradient Echo Imaging

Gradient echo imaging forms the foundation of many applications on modern magnetic
resonance imaging (MRI) systems78. Gradient echo imaging has found many practical
applications where rapid imaging with low power deposition is required79, including
dynamic cardiac imaging, MR angiography, perfusion imaging, and functional MR
studies. The gradient echo acquisition represents the most basic MRI experiment: after
excitation of spins in the imaging volume with a radio-frequency (RF) pulse, a readout
gradient is applied and the signal is sampled80. Gradient echo sequences form the basis
for much of the imaging work described in this thesis.

1.2.1

Gradient echo signal: Magnitude

After RF excitation, transverse magnetization (i.e. which generates signal) will decrease
in magnitude with time, due to thermodynamic effects. This process is called transverse
relaxation, and is characterized by an exponential rate of !! , or its inverse, the decay time
constant !! 81. !! is inversely proportional to water concentration. !! will also increase in
the presence of iron. Variations in magnetic field within the imaging voxel cause spins to
precess at a range of frequencies resulting in dephasing, or loss of coherence. In gradient
echo imaging, this dephasing is not reversed. Therefore, the measured magnitude of the
vector sum of these spins is reduced compared to what is expected due to !! decay alone.
This additional field-induced decay is characterized by rate !!! , or its inverse, the decay
time constant !!! 79. !!! is dependent on the sample and machine, and will increase with
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increasing iron concentrations in the imaging volume. The effective transverse relaxation
of magnetization magnitude occurs due to both thermodynamic (!! ) and field-induced
(!!! ) effects, and is characterized by a rate !!∗ (Eq. 1.1), or equivalently, its inverse, the
relaxation time !!∗ (Eq. 1.2).
[1.1]

[1.2]
The magnitude (S) of gradient echo signal therefore depends on the effective transverse
relaxation rate, in addition to the time at which the signal is sampled (i.e. the echo time,
TE), and the steady state signal (S0), as described in Eq. 1.3.
[1.3]

1.2.2

Gradient echo signal: Phase

Magnetization, which gives rise to MR signal, is a vector, having both magnitude and
phase. Once magnetization is excited into the transverse plane, it precesses about the
magnetic field at a frequency that is linearly related to magnetic field; equivalently,
frequency offset (Δω) from resonance is proportional to the shift (ΔB) from the main
magnetic field	
  as in Eq. 1.4, where the constant of proportionality (γ) is the gyromagnetic
ratio.
[1.4]
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The phase (ϕ) of magnetization represents the difference in phase accrued by some time
(TE) compared to on-resonance spins (i.e. those spins where Δω=0), as in Eq. 1.5a; or,
after considering the relationship presented in Eq. 1.4, as in 1.5b.
[1.5a]
[1.5b]
The phase of the signal measured for a given voxel is the phase of the vector sum of all
magnetizations within the voxel. In reality, there will be a range of magnetic fields within
the voxel; in other words, it would be inappropriate to assume a single value of ΔB for the
entire voxel. The interpretation of voxel phase is further complicated by the fact that a
range of transverse relaxation times within a voxel will cause magnetizations to
contribute differentially to measured phase, especially at increasing TEs. The measured
phase of a voxel can be considered related to an average	
  ΔB	
  within the voxel, weighted
towards positions within the voxel with the largest magnetization at the TE.
The distribution of magnetic susceptibilities within the imaging volume of interest, for
example the brain, gives rise to changes in ‘local’ (ideally, microscopic and mesoscopic)
magnetic field (Blocal)82. However, inhomogeneities in the main magnetic field and abrupt
magnetic susceptibility interfaces (for example, at the sinuses) result in a so-called
‘background’ field (Bbackground). Any deviation from the main field	
   ΔB, to which
magnetization phase is proportional (Eq. 1.5b), is thus the superposition of deviations due
to local and background effects83, as in Eq. 1.6.
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[1.6]
Background contributions are generally undesirable and efforts are made to remove them
from the phase image before further processing. The background field tends to vary
slowly over the image; therefore its effects on phase can be removed with spatial highpass filtering. A number of such techniques have been proposed to remove these
unwanted contributions from phase, including heuristic approaches (homodyne
filtering84, fitting of high order polynomials85) and application of physical models (dipole
fitting86, SHARP filtering87). In reality, the classification of field shifts into ‘local’ and
‘background’ is quite arbitrary and in many cases, appears to be retrospectively defined:
those contributions which can be removed with by the implemented spatial filter are
deemed ‘background,’ and everything else, ‘local.’ 	
  
In clinical practice, phase data are nearly always discarded, with exceptions limited to
phase contrast angiography88, where phase is sensitized to flow speed by application of
magnetic field gradients. In research settings, phase contrast has been exploited for an
increasing number of applications in recent years, including calculation of quantitative
susceptibility maps89, measurement of cerebral metabolic rate of oxygen90, and
measurement of iron concentrations91. Due to field shifts that arise in the presence of
deoxygenated blood, phase plays a crucial role in susceptibility weighted imaging, as
described below.
Ultimately, both phase and !!∗ (and thus magnitude, as in Eq. 1.3) are dependent on the
distribution of magnetic field within the imaging volume. Differences in phase are related
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to differences in ΔB between voxels. Differences in magnitude may be attributed to
differences in ΔB experienced by magnetization within voxels (i.e. differences in !!!
between voxels) in addition to differences in !! .

1.2.3

Blood oxygenation level dependent (BOLD) effect

The BOLD effect represented a major breakthrough in the visualization of capillaries,
venules, and veins by using deoxyhemoglobin as an intrinsic contrast agent92. In blood,
the transverse relaxation times (!! and !!∗ ) are a function of deoxyhemoglobin content
and thus of blood oxygenation. As oxygenation increases, deoxyhemoglobin
concentration decreases, and the relaxation times – and thus the signal in !! or !!∗
weighted images – will increase.
Early work in animals and humans demonstrated that the BOLD effect could be exploited
to image veins, visibility of which was a function of available signal-to-noise ratio,
degree of oxygenation, and size of vessel93. Shortly thereafter, the BOLD mechanism
found use in functional MRI, where the increase in oxygenation that accompanies neural
activation results in increase of MRI signal94.
The study of Lai et al. was the first to describe efforts to enhance BOLD contrast in
gradient echo images to improve visibility of veins95. In that study, a commutator filter
was described that incorporated information from the complex image into the magnitude
image, wherein some venous contrast was present and attributable to the BOLD effect.
This formed the basis for MR venography with susceptibility weighted imaging (SWI)
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where phase data is used directly to enhance BOLD contrast in magnitude images, as
described in the subsequent section.

1.2.4

Susceptibility weighted imaging (SWI)

Extending the work of Lai et al., Reichenbach formally described imaging small veins
using the phase image explicitly to enhance magnitude contrast96. This technique was
originally referred to as BOLD MR venography, however it has since been named
susceptibility weighted imaging. At 3 T and with a resolution of 0.5x0.5x1.0 mm3, SWI
was estimated to visualize veins with diameters on the order of 100 to 200 μm97, which
speaks to the remarkable ability of SWI for visualizing small veins.
In SWI processing83, the low spatial frequency components of the phase image
(putatively those arising from ΔBbackground in Eq. 1.6) are first removed using homodyne
filtering. The resulting filtered phase image is used to create a phase mask. The typical
function98 used to create this mask image is described in Eq. 1.7, and illustrated with
Figure 1.1, although other functions are certainly possible. Effectively, this particular
function scales negative phases of –π to 0 rad (-180° to 0°) linearly from 0 to 1, and sets
all positive phase (0 to +π rad, i.e. 0° to +180°) to 1.

[1.7]
Due to paramagnetic deoxyhemoglobin99, voxels containing veins typically will have
negative phase and thus will be assigned values less than 1 in the phase mask.
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Figure 1.1 SWI processing. Phase and magnitude data are reconstructed. The background
field contributions to phase are removed using homodyne filtering. The filtered phase
image (Φ) is converted to a mask [f(Φ)], using the plotted function. The mth power of the
mask is multiplied with the magnitude image. A minimum intensity projection (mIP)
over 10 mm is shown, where veins are readily apparent.
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By multiplying the phase mask with itself several times, contrast between veins and
surrounding tissue can be enhanced. However, while venous contrast can be accentuated
by increasing the exponential power of the phase mask, generally referred to as m, doing
so also increases noise, therefore the optimal value of m must be carefully considered100.
Multiplication of the mth power of the phase mask with the magnitude image (wherein
veins may have some contrast already in part due to the BOLD effect) results in enhanced
venous contrast, i.e. veins appear darker. If illustrating venous vessel contiguity is the
goal of the study, adjacent slices can be viewed as a minimum intensity projection (mIP).
These steps are illustrated in Fig. 1.1.
The technical foundations of SWI processing were well established by the early 2000’s
and work has continued to optimize acquisition101 and post-processing parameters100,102.
One component of the post-processing chain that is very flexible and thus a research
target is the mask function. While the linear mask function described above (Eq. 1.7) is
the commonest function, other functions have been proposed for specific applications,
such as improving contrast of veins for oblique acquisitions103, improving contrast of
implanted microelectrodes104, and kidney imaging105.
Since its earliest descriptions as a technique for venography, SWI has found uses in
visualizing other tissues in the brain, such as blood products, iron, and calcium. As a
result, major clinical applications of SWI are numerous106 and include investigations for
trauma, stroke, cerebral amyloid angiopathy, and tumor grading.
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1.2.5

Multi-echo gradient echo and !!∗   relaxometry

Extension of gradient echo to multiple acquisitions of signal (i.e. at a series of TEs) after
the RF excitation allows multiple contrasts to be acquired in the same sequence. By
serially sampling the decay of magnetization, one obtains a dataset from which !!∗ can be
measured for each voxel. The most basic approach to measuring !!∗ involves fitting the
magnitude data from each voxel as a function of TE to the exponential decay function107
(Eq. 1.3). Phase data can be incorporated into the curve fit in order to eliminate
undesirable increases in !!∗ due to magnetic field inhomogeneity across the voxel108, an
effect that is more pronounced with increasing voxel size. !!∗ can also be measured by
summing measurements of !! and !!! , although this may require novel pulse
sequences109.
Each of !! , !!! , and !!∗ has been used in the study of iron in chronic brain disorders110,
however for the following reasons, !!∗ appears to be the most widely used. A linear
relationship between local iron concentration and !!∗ has been chemically validated85;
moreover, !!∗ images show contrast that correlates well with histological iron stains111.
Well-known trends in brain iron accumulation with age have been reproduced with !!∗
mapping107. !!∗ has been used to study brain iron accumulation in chronic brain disorders
including multiple sclerosis67, Parkinson’s112, Alzheimer’s113, essential tremor114, and
non-specific demyelination115. In the brain, !!∗ is also sensitive to myelin content and has
been used to characterize location, direction, and myelination of white matter fiber
bundles116. !!∗ mapping in non-brain is also useful for iron studies, such as in the liver117
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and heart118. Like !! , !!∗ will decrease in the presence of increasing water concentration;
and like !!! , !!∗ will increase in the presence increasing field inhomogeneity, although in
the brain, iron and myelin are the major sources of such inhomogeneity.
SWI images and !!∗ maps contain useful and potentially complementary information
regarding the anatomy and quantitation, respectively, of different perturbers in the brain.
However, SWI processing involves only a single-echo gradient echo dataset, whereas !!∗
mapping requires multiple echoes. Multi-echo SWI processing has been proposed in
previous studies103,108 and allows generation of high-quality venograms in addition to
intrinsically co-registered !!∗ maps. However, no previous work has identified the
optimal method by which a series of echoes can be combined into a single SWI image.
This is the focus of Chapter 2 of this thesis.

1.3

Venous Drainage of the CNS

Owing largely to the well-established but unexplained association of MS lesions and
small veins in the brain, a number of theories have been proposed in the last century that
attempt to connect circulatory abnormalities to MS etiology. In the 1930’s, Putnam
studied obstructed venous flow in the cerebral veins of dogs119, and described similarities
between resulting symptoms and those experienced by patients with MS. In the late
1970’s and 80’s, Schelling postulated that venous reflux into the CNS may be associated
with MS120. In the last decade, a theory proposed by an Italian vascular surgeon
suggested

a

direct

link

between

occlusion

of

extra-cranial

veins,

cerebral
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microhemorrhages, and iron-mediated inflammation in MS121. These theories have been
met with substantial scientific evidence to the contrary, but questions still remain. Are
venous abnormalities associated with MS? And if so, do they represent an integral
component in disease pathogenesis? Is there an association with iron deposition? We
attempt to address these issues, in part, in Chapter 4 of this thesis. An overview of the
topic is presented here.

1.3.1

Normal drainage of the CNS

The vascular system that drains the cerebrum can be divided into two parts: the
superficial system and deep cerebral venous system122. The superficial system consists of
superficial cerebral veins that run along the cortex and receive blood from subcortical
white matter and cortical grey matter. These veins empty into dural sinuses, which
include the occipital sinus and superior sagittal sinus. These sinuses flow posteriorly and
inferiorly and merge at the confluence of the sinuses. The deep cerebral system drains
deep white matter and deep grey matter via the internal cerebral veins and the Vein of
Rosenthal. The site of drainage of this system is the great vein of Galen, which then
empties into the straight sinus123. The straight sinus runs posteriorly and joins with the
superficial sinuses at the confluence of sinuses. The confluence then bifurcates into the
left and right transverse sinuses, through which blood flows anteriorly as these vessels
become the left and right sigmoid sinuses. The sigmoid sinuses turn inferiorly as they
become confluent with the left and right internal jugular veins (IJVs) at the cranial base.
These veins are identified in a time-of-flight magnetic resonance venogram in Figure 1.2.
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Figure 1.2 Sagittal maximum intensity projection of time of flight magnetic resonance
venogram of major intracranial veins. A sinus (more properly, a dural venous sinus) is a
venous channel, but unlike a vein, the walls of a sinus are composed of dura mater.
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Veins of the cerebellum drain into adjacent sinuses, including the transverse, occipital,
and straight sinuses123. The veins of the brainstem form a venous plexus (a network or
tangle of veins), parts of which may become continuous with spinal veins, or empty into
nearby sinuses.
In addition to draining blood from the brain, the IJVs also drain much of the skull and
deep parts of the neck and face122. Each IJV descends parallel to the ipsilateral carotid
artery: at its termination, the IJV joins with the subclavian vein to form the
brachiocephalic vein. This vein in turn merges with the contralateral vessel and empties
into the superior vena cava. Slightly superior to the IJV termination, the inferior bulb is a
dilation of the IJV that is present in most individuals. Superior to the bulb are a pair of
valves124.
The vertebral vein forms from numerous tributaries of internal venous plexuses within
the vertebral canal, which exit the canal at the first cervical vertebra124. The vein
descends through transverse foramina of the cervical vertebra as a plexus and emerges
from the transverse foramen of the sixth cervical vertebra. Subsequently, the vertebral
vein empties into the brachiocephalic vein, but also communicates with deep thoracic,
lumbar, and intercostal veins. The azygos vein is the final collector for this system, and
represents an alternative pathway for blood to return to the right atrium125.
In addition to the IJVs, numerous tributaries, which are variable between individuals,
may form anastomoses (cross-links) between veins of the neck. As such, the veins of the
neck cannot necessarily be entirely separated122 and it is not possible to define a single
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normal anatomy for drainage of the CNS. The main veins of the neck are identified in a
magnetic resonance venogram in Figure 1.3.

1.3.2

Chronic cerebrospinal venous insufficiency (CCSVI)

An Italian vascular surgeon, Paulo Zamboni, first proposed parallels in the inflammatory
environment of MS lesions and ulcers associated with chronic venous disease in 2006,
and suggested that a similar pathological substrate – impaired venous drainage – was to
blame121. Specifically, Zamboni proposed that inflammation in both diseases was irondependent. He interpreted reflux during Valsalva maneuver in a patient with MS as
evidence of insufficient venous flow, and suggested that such insufficiency might lead to
iron deposition and inflammation upstream, i.e. in the CNS.
In subsequent studies, Zamboni interrogated intracranical126 and extracranial127
hemodynamics in a larger group of MS patients using ultrasound and selective
venography. Five ultrasound-measureable parameters were identified to be typical of a
condition Zamboni called CCSVI. A subject in whom two or more parameters were
detected was said to have CCSVI. A diagnosis of CCSVI was found to overlap perfectly
with a diagnosis of MS128. In interpreting this remarkable association, Zamboni suggested
that structural abnormalities in the IJVs and azygos vein (which are main outflow routes
for venous blood from the brain, as described in section 1.3.1) resulted in venous reflux,
increased intracranial pressure, extravasation of red blood cells, and ultimately ironmediated inflammation.
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Figure 1.3 Coronal maximum intensity projection of time of flight magnetic resonance
venogram of major cervical veins. Vertebral veins are not readily separable from other
veins and have not been labeled.

27

Subsequently, an association between venous abnormalities and MS became the focus of
intense scrutiny. Several ultrasound studies failed to reproduce as strong of association
between CCSVI and MS as reported initially129,130, or failed to detect CCSVI in MS at
all131,132. In rebuttal, Zamboni claimed this was due to lack of operator training for
sonography133. Reports of normal intracranial pressure134 and normal cerebrospinal fluid
(CSF) ferritin levels135 in MS patients were also inconsistent with the CCSVI model.
Weinstock-Gutman et al. reported CCSVI in MS patients, however found no relation to
clinical disability, raising further questions about the relevance of the CCSVI
condition136. Indeed, major questions about CCSVI remain unanswered, including
whether it exists at all, and if so, if it is associated with MS137.
Fueling the controversy surrounding CCSVI, Zamboni reported on an endovascular
surgery for CCSVI, describing it to be initially successful at treating extracranial venous
stenoses138. Reports of positive clinical outcomes in patients were taken with
considerable caution given the lack of blinding or control wings in these studies139.
Enthusiasm for the procedure was increased dramatically by media reports despite the
absence of any conclusive evidence that treatment of CCSVI was indicated in MS140.
While sonography is the only imaging technique with which CCSVI can be diagnosed
(CCSVI is, after all, an ultrasound-defined entity)128,141, it suffers from several setbacks
including a large dependence on operator training. For this reason, and because
sonography is foreign to conventional MS studies, a number of research groups have
investigated the suitability for magnetic resonance imaging for studying extracranial
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veins in patients with MS142-144. MRI techniques are less dependent on operator training
and allow 3D visualizing of the intra- and extra-cranial vasculature. In general, these
studies suggest that time-of-flight (TOF) magnetic resonance venography (MRV) may be
a suitable method by which to visualize the internal jugular veins. While the neurological
community grows increasingly reluctant to consider a role for CCSVI in MS, recent
MRV studies have shown structural abnormalities of the IJVs (such as narrowing or
flattening) to be more prevalent in MS patients than healthy controls143,144. Such studies
have used a subjective or categorical rating scale to classify vessel anatomy. It is our
belief that a quantitative measure of vessel caliber would be more useful in such work.
The suitability of TOF MRV for quantitative measures of IJV caliber is the focus of
Chapter 3 of this thesis, and in Chapter 4, we describe the application of such
measurement techniques in patients with CIS.

1.4

In This Thesis

This thesis is concerned with work done thus far in an on-going longitudinal MRI study
of iron in patients with CIS at high risk of MS diagnosis. Given the unresolved question
regarding iron’s role as either a cause or consequence of MS, we identify the following as
the objective for this thesis: to characterize MRI biomarkers associated with iron
deposition in patients with early presentations of MS. Specifically, we identify the
following specific aims, each of which is the basis for a subsequent chapter. Specific
Aim 1: to optimize an MRI post-processing technique to create both cerebral venograms
and quantitative images for measuring iron. Specific Aim 2: to establish reproducibility
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of quantitative measures of IJV caliber, given the proposed (and increasingly tenuous
role) for these veins in MS pathogenesis. Specific Aim 3: to compare relative levels of
iron between CIS patients and healthy controls, in order to determine the spatial
distribution of any increased iron present early in the disease. Specific Aim 4: to
determine if, using techniques developed in this thesis, venules can be detected within
lesions in CIS patients. Such venules may be involved in iron deposition53 and may also
have predictive value for subsequent MS diagnosis145. Thus, with work proposed here,
we are able to investigate a role in early MS for not only iron but additionally veins that
drain the CNS - including cerebral venules (about which lesions are centred) and cervical
veins, which ostensibly have a role in MS pathogenesis as mediators of iron deposition.

1.4.1

Specific Aim 1: Multi-echo SWI

Multi-echo SWI allows for generation of an image with contrast derived from the
distribution of susceptibility within the brain (i.e. a SWI image, useful for visualizing
veins), in addition to a quantitative !!∗ map, the latter being particularly useful for
quantifying iron. It has been shown that !!∗ -weighted magnitude images are sufficient for
discrimination of MS plaques from other non-specific lesions in white matter at ultrahigh field strengths, based on the presence of a central vein76. However, at clinical field
strengths the endogenous contrast in the !!∗ -weighted magnitude is insufficient for this
type of analysis75. Multi-echo SWI may provide the necessary boost in venous contrast at
clinical field strengths to facilitate improved diagnostic specificity based on the presence
of a central vein. With this in mind, Chapter 2 of this thesis describes efforts to optimize

30

multi-echo SWI processing and characterize improvements in the contrast of a number of
structures in healthy controls. We also perform measurements of !!∗ and validate our
measurements against previously reported values. Part of this work has been accepted for
publication in the American Journal of Neuroradiology. This sequence and postprocessing form the methodological foundation for our on-going longitudinal study of
CIS patients.

1.4.2

Specific Aim 2: Time of flight MRV reproducibility

As described in Section 1.3.2, an interesting, if not altogether convincing, theory has been
proposed that attributes MS pathogenesis to extra-cranial venous pathology resulting in
cerebral iron deposition. Most MR studies of CCSVI examine the IJVs with a categorical
rating scale144, which may in fact be suboptimal. In Chapter 3 of this thesis, we
investigate quantitative measures of IJV caliber including the cross-sectional area as
measured from TOF MRV. Specifically, this chapter is concerned with establishing the
inter-scan reproducibility of these metrics in healthy controls.

1.4.3

Specific Aim 3: Study of iron in clinically isolated syndromes

In Chapter 4 of this thesis, we use !!∗   maps to establish differences in iron between our
study’s cohort of CIS patients and healthy controls. First, changes in !!∗ with age are
estimated from the normal cohort. Next, the expected normal contributions to aging are
removed from !!∗ datasets for both patients and healthy controls. For each voxel in the
brain, statistical testing is used to determine if there are any differences between groups
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in age-corrected !!∗ and thus, potentially iron. For clusters of voxels where significant
differences were found, regions of interest are defined. Correlations of the average !!∗ in
each region of interest with additional imaging and clinical measures are investigated in
order to explain the observed differences. To assess the predictive value of increased !!∗
for MS diagnosis, we compare !!∗ increases between those CIS patients who have been
diagnosed with MS since recruitment and those who remain unconverted. Additionally,
as a potential explanation for increased iron in MS, we explore the cross-sectional area of
the IJVs in both patients and healthy controls using methodology proposed in Chapter 3.

1.4.4

Specific Aim 4: Imaging central veins in MS lesions

It has been proposed that a large fraction of lesions with MRI-detectable penetrating
veins in potential MS is predictive of future MS diagnosis; however, questions remains
about the practical feasibility of this technique. In Chapter 5 of this thesis, we employ
tools proposed in Chapter 2 (multi-echo SWI) to characterize the visibility of veins
within white matter hyperintensities (WMHs). Using multi-echo SWI, WMHs in all
subjects are rated for the presence of a central vein. The prevalence of veins within
WMHs is compared between healthy controls, CIS patients who have not yet converted
to MS (after approximately 1 year of follow up), and CIS patients who have converted to
MS. Moreover, the predictive value of a high percentage of lesions with central veins for
conversion to MS is evaluated on a patient-by-patient basis.
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The last chapter of this thesis summarizes the work performed for this thesis and also
briefly discusses some prospective analyses to be carried out on study data.
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2

Comparison of multi-echo post-processing schemes for
susceptibility weighted imaging with use of linear and
non–linear mask functions
2.1

Introduction

Susceptibility weighted imaging (SWI) is a magnetic resonance imaging (MRI) technique
that exploits the effect of variations in magnetic susceptibility (the degree of
magnetization of a material in response to an applied magnetic field) on gradient echo
signal to produce enhanced image contrast. Most MRI studies reconstruct only the
magnitude image; phase is generally discarded. However, the phase data contain
potentially useful information about inclusions in the imaging volume that change the
local magnetic field, i.e. of non-homogeneous magnetic susceptibility. SWI processing
allows this information to be incorporated into the magnitude image since the underlying
structure may not necessarily be visible on magnitude alone1.
SWI was originally used to produce high-resolution venograms2. SWI has found
additional uses in clinical and research settings due to its sensitivity to other
physiologically relevant magnetic field perturbers such as blood products3, iron4 and
calcium5. However, single-echo SWI is useful in the visualization but not the
quantification of field perturbers. Modifications of SWI allow simultaneous
quantification of the nature or amount of the perturber. For example, the effective
transverse relaxation rate (!!∗ ), which can be extracted from multi-echo gradient echo
A modified version of this chapter has been published in the American Journal of Neuroradiology. Quinn
MP, Gati JS, Klassen LM, Lin AW, Bird JR, Leung SE, Menon RS. Comparison of multiecho processing
schemes for SWI with use of linear and non-linear mask functions. Am J Neuroradiol AJNR. DOI:
10.3174/ajnr.A3584. 2013, © by American Society of Neuroradiology.
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data via voxel-wise curve fitting, is a metric that scales linearly with iron concentration in
the brain6.
Brainovich et al.7 described a post-processing scheme for dual-echo gradient echo data.
In this scheme, average phase and average magnitude volumes were generated and
subsequently used to produce a single SWI volume. Denk and Rauscher8 used a multiecho acquisition with five echoes to produce five SWI volumes that were subsequently
averaged to produce a single average SWI volume. They reported improvements in
contrast to noise ratio (CNR) of veins compared to conventional SWI. Additionally, they
described computation of !!∗ maps as a natural extension of the multi-echo acquisition. In
all cases, a conventional linear phase mask function for SWI was employed. The use of
alternative mask functions theoretically results in increased CNR of cerebral veins9,
although this claim has not been rigorously tested in vivo.
There are two main goals of this work: first, a comparison of three SWI post-processing
schemes (single echo and two multi-echo methods); and second, a comparison of the
conventional (i.e. linear) mask function with a novel non-linear mask function. We
identified the following objectives: (i) to describe and outline modifications to previously
published multi-echo SWI, as well as describe a non-linear mask function, (ii) to
optimize the number of mask function multiplications for all combinations of postprocessing scheme and mask function; and, (iii) to compare all post-processing schemes
and mask functions in vivo using both quantitative and radiological assessments.
This work has been presented, in part, at the 20th Annual Meeting of the ISMRM10.
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2.2

Methods

Processing was performed in MATLAB (The MathWorks, Inc., Natwick, MA) and FSL
(FMRIB, Oxford, UK). Statistical analyses were performed in SPSS (IBM, Armonk,
NY).

2.2.1

SWI post-processing schemes

Three post-processing schemes were compared: one for single-echo SWI and two for
multi-echo SWI. First, single-echo SWI processing involves background phase removal
using the homodyne method11, generation of a phase mask, and multiplication of the mth
power of the mask by the magnitude image12.
Second, the multi-echo SWI method of Denk and Rauscher8 was modified, and herein is
referred to as the post-average method. Post-average multi-echo SWI involves singleecho SWI processing on data from each echo, and averaging of the resulting images.
Denk and Rauscher prescribe this technique with a linearly (in echo time) increasing
homodyne filter width to remove background contributions to phase from each echo in
order to account for the additional phase wrapping at longer echo times. We used a
constant (with echo time) filter size, as a compromise between eliminating phase wraps in
later echoes and preserving the relevant contrast between echoes in a consistent manner.
Third, a frequency-based method for multi-echo SWI was used, and is based upon the
method described initially by Brainovich et al.7. For the image volume reconstructed
from each echo, the background phase was removed using the homodyne method.
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Successive phase images were then temporally unwrapped using MATLAB’s 1D unwrap
function on the echo time dependent voxel data. Each unwrapped phase image was then
divided by its corresponding TE to produce a frequency image. A weighted average of
frequency was calculated from these individual frequency images: weights were inversely
proportional to the variance of the frequency: (magnitude)2(TE)2. A mask was computed
from the average frequency image, and its mth power was multiplied by the average
magnitude image for that slice. This method is similar to what has been described by
Brainovich et al.7 but additionally involves the temporal unwrapping of phase, as well as
masking the weighted average of frequency maps rather than the arithmetic mean of the
phase images. While the mean of the frequency maps is a physical and intuitive quantity,
the mean of the phase images used by Brainovich et al.7 is not logical from a physical or
mathematical perspective.
For the homodyne filter, a 2D Hann window (one period of a raised cosine) with
dimensions equal to 30% (for multi-echo) or 20% (for single-echo) of the respective
matrix dimensions, rounded to the nearest integer, was employed. This constant width
filter, in conjunction with the temporal phase unwrapping that was used, resulted in the
ability to remove all relevant phase wraps.

2.2.2

SWI mask functions

Two different mask functions were compared. First, the conventional linear mask
function was used. In general form, the linear mask, L, is defined as follows:
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 0

if x < −X
(x + X) if −X ≤ x ≤ 0
L(x) =

1
if x > 0
.
1
X

[2.1]

For single-echo and post-average, X=-π rad is used, with x in radians. For frequencybased SWI where x is in units of Hertz, X is set to the equivalent value:
(-π rad)(1 cycle/2π rad)(1/TEaverage)=18.2 Hz, where TEaverage is the average of the echo
times used (described below).
Second, a non-linear mask function was used. This Hann-derived mask, H, is defined as
follows:

 0�
� πx ��
1
1
+
cos
H(x) =
X
 2
1

if x < −X
if −X ≤ x ≤ 0
if x > 0
.

[2.2]

The values X and x can be expressed in either units of phase or frequency. X was set to π
(for single-echo and post-average) or the equivalent value of 18.2 Hz (for frequencybased SWI). Compared to the linear filter, it was expected that this filter would result in
reduced image noise and increased contrast for negative phase/frequency structures.

2.2.3

MR imaging

All scanning was performed on a 3T MRI scanner (TIM Trio, Siemens Medical
Solutions, Erlangen, Germany) using a 32-channel head coil. For evaluation and
comparison of different SWI post-processing schemes, 10 healthy volunteers were
scanned (7 women/3 men; mean±standard deviation age=28±7 years). Data were
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collected using a single-echo 3D gradient echo (TE/TR=20/30 ms, BW=80 Hz/pixel,
TA=6:28, fully flow-compensated) and multi-echo 3D gradient echo sequence (TE1=10
ms, echo spacing=7 ms, 6 echoes, TR=52 ms, BW=160 Hz/pixel, TA=11:12, first echo
fully flow-compensated). For both sequences, common parameters were: matrix, 448 x
336 x 60; field of view, 224 x 178 x 60 mm3,; flip angle, 12°; slice oversampling, 12.5%.
Both acquisitions were accelerated with GRAPPA (R=2, reference lines=24). Phase data
from each channel were combined on-line using vendor software. This study was
approved by the institutional review board. Informed consent was obtained in writing
from all participants.
Six SWI volumes were created per subject: three post-processing schemes with two mask
functions each. The single-echo magnitude volume was registered to the first echo
magnitude of the multi-echo volumes to allow careful comparison of the different
methods on individual vessels or regions even if motion were present between the
different volumes.

Single-echo SWI volumes were computed, following which the

magnitude registration parameters were applied.

2.2.4

Numerical optimization

A 2D numerical phantom was created to evaluate the CNR of a vein using different postprocessing schemes and mask functions. The purpose of this simulation was to optimize
the number of mask multiplications, m, for different post-processing schemes. The
phantom consisted of a 512x512 array. All pixels were assigned values of the effective
transverse relaxation time, !!∗ (32 ms), and equilibrium signal, S0 (425), based on their

54

measured values in white matter (WM) in the in vivo multi-echo data. One column was
designated the vein compartment and assigned a frequency which was varied for different
trials. All other pixels were assigned a frequency of zero for all trials. This is similar to a
previously described simulation to optimize the number of mask multiplications for
conventional SWI12.
Data were simulated by creating magnitude and phase image pairs for different TEs. At a
given TE, signal magnitude was calculated according to:
S(T E) = S0 exp(−T E/T2∗ ).

[2.3]

Phase was calculated as (frequency)x(TE). Each magnitude and phase pair was converted
into real and imaginary images, to each of which normally distributed noise with standard
deviation of 18 was added to ensure comparable signal-to-noise ratio (SNR) in simulated
data when compared to periventricular WM using our acquisition parameters. The noisy
real and imaginary images were then converted back to magnitude and phase.
A multi-echo data set was simulated by creating magnitude/phase pairs for TEs of 10, 17,
24, 31, 38 and 45 ms. From the same simulated multi-echo data, one multi-echo SWI
image was generated according to each of the four possible combinations of multi-echo
post-processing scheme (post-average and frequency-based) and mask function (linear
and non-linear).
Single-echo data were simulated by creating one magnitude/phase pair at TE=20 ms.
Noise was decreased by a factor of 20.5 to simulate decreased noise accompanying the
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reduction in bandwidth from 160 Hz/pixel in the multi-echo acquisition to 80 Hz/pixel in
the single-echo acquisition. Additionally, the WM S0 was decreased by 16% to account
for the reduction in steady state signal accompanying the decrease in TR. For the
simulated single-echo data, one SWI image was produced with each mask function.
Contrast was measured as the difference in mean signals between two regions of interest
(ROIs) in the SWI volumes: one placed in the vein compartment, and one in the WM
compartment. The CNR was calculated as this contrast divided by the standard deviation
of the signal in the latter ROI, which is the standard definition of CNR used in SWI
numerical optimization13.

2.2.5

Visual optimization

Values of the mask power, m, were also optimized by three radiology residents, each with
29 months experience, who rated SWI images from four volunteers. For each volunteer,
image volumes included each of the six SWI combinations processed with a range of m
values. Images processed with the linear mask function were processed with m’s from 0
to 11, incremented in steps of 1. Images processed with the non-conventional filter were
processed with m’s from 0 to 55, incremented in steps of 5. This larger range and coarser
increment of m values was found to yield a similar range of contrasts to the images
processed with the conventional mask. Accordingly, raters were shown 24 sets of 12
volumes. The raters were not blinded to the value of m, but each set was presented in a
random order to ensure experience from early sets did not influence rating of later sets.
Rating instructions were as follows: “For each set, identify the single value of m which is
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optimal. When considering optimal m, consider SWI quality from a radiological
standpoint. Please consider how structure contrast as well as image noise are affected by
choice of m. Specifically, you should consider the visibility of veins (both small veins
such as those at the lateral ventricles, and large veins) as well as other structures that may
be targeted with SWI such as: red nucleus, subthalamic nucleus, globus pallidus.” Each
rater performed rating independently. To evaluate inter-rater agreement, two-way mixed
average measures interclass correlation coefficient was calculated for the pooled ratings.

2.2.6

Measurements of !!∗

!!∗ images were calculated by performing a voxel-wise curve fit of the magnitude time
curve to Eq. 2.3 above. The fitting was performed using the Levenberg-Marquardt
algorithm for non-linear least-squares curve fitting.

2.2.7

ROI analyses

For in vivo data, ROI analyses were used to compare optimized SWI techniques. For
each subject, ROIs were drawn in the right hemisphere of single-echo, linearly masked
SWI volume and propagated into the other volumes. SNR was approximated in the
frontal WM of all subjects as the mean divided by standard deviation of the signal in the
ROI. CNR was measured between various anatomical structures [globus pallidus (GP),
optic radiations (OR), periventricular veins, subthalamic nucleus (STN), and red nucleus
(RN)] and adjacent WM as the difference between mean values of signal in two ROIs
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(one in the structure of interest, one in adjacent WM) divided by the standard deviation of
signal in the WM ROI.

2.2.8

Visual comparison

The same three raters evaluated the optimized SWI images with respect to visibility of
different structures. For each of the ten volunteers, the six different SWI volumes were
assigned a random letter for blinding purposes. Raters were instructed to rank the
volumes from best (rank 1) to worst (rank 6) for different structures. Specific instructions
were: “consider: the contrast of the structure with surrounding tissue, the ability to
resolve its borders, and how image noise influences visibility.” Visibility was ranked for
the same structures in which CNR was measured. Qualitative impression of SNR in
frontal WM was also ranked. Images were rated for severity of artifacts at sinuses from
least severe (rank 1) to most severe (rank 6).
To evaluate inter-rater agreement, interclass correlation coefficient was calculated on
rankings of each structure analyzed. For each volunteer, for each combination of
processing scheme and mask function, the three ranks assigned by the raters were
averaged to create a mean rank. To separately test the significance of the two main effects
(processing scheme and filter), for each level of each main effect, mean ranks were added
across all levels of the other main effect. Non-parametric related samples tests were then
used to compare all levels of a given effect: Friedman test for scheme, Wilcoxon signedrank test for filter. Where appropriate, the Wilcoxon test was used post-hoc with
Bonferroni correction.
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2.3
2.3.1

Results

Optimization of m

Plots of CNR as a function of the mask power m are presented (Figure 2.1) for several
different choices of the frequency of the vein compartment of the numerical phantom.
Optimal values of m depend strongly on frequency of the vein; minimum and maximum
values of optimal m over the range of frequencies investigated are presented in Table 2.1.
According to simulation, greater CNR is achievable with the non-linear mask, although
typically larger values of m are required. Simulation predicts that the frequency-based
method allows the greatest CNR, and that both multi-echo methods are superior to singleecho SWI.
Optimization of m was also performed via visual rating of images. To measure the
optimal value of m for a given processing combination, the median (across the four
volunteers) of the median (across the three raters) is reported in Table 2.1. In all cases,
the optimal value as determined by the raters falls within the range of optimal values
predicted by simulation. The interclass correlation coefficient was found to be 0.96,
indicating excellent inter-rater agreement. When implementing different SWI techniques
herein, we use the values of m determined to be optimal by the raters.
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Figure 2.1 CNR versus number of mask multiplications (m) for different SWI postprocessing schemes (red: single-echo, blue: post-average, green: frequency-based) and
mask functions (solid: linear, dashed: non-linear) as simulated for a vein of varying
frequency in WM. Simulated frequencies were: -1.0 Hz (a), -2.5 Hz (b), -5 Hz (c), -10.0
Hz (d).
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Table 2.1 Optimization of m
Simulation

Single echo

Post-average

Frequency-based

a,b

Radiologist Rating

Min.

Max.

optimal ma

optimal mb

Optimal m (minc,maxd)

Linear

4

17

6 (4,7)

Non-linear

11

>60

35 (20,35)

Linear

3

15

7 (5,10)

Non-linear

14

>60

35 (25,45)

Linear

3

15

5 (2,7)

Non-linear

8

>60

25 (20,40)

Minimum, maximum values, respectively, of m that yield maximum CNR for any
frequency of vein simulated.
c,d
Minimum, maximum values, respectively, assigned by any of the three raters.
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2.3.2

In vivo data

Minimum intensity projections through 4 mm for a subset of a slice at the level of the
basal ganglia are shown in Figure 2.2 for all permutations of post-processing scheme and
mask function, using optimal values of m from Table 2.1.
In general, the non-linear mask function results in improved noise characteristics
compared to the linear filter, and its use also dramatically enhances contrast in some
regions, for example for large veins (arrow in Fig. 2.2f) and at the edges of the basal
ganglia (arrowheads in Fig. 2.2f). Small veins which are not visible in single-echo SWI
are readily detected in all implementations of multi-echo SWI, such as at the horns of the
ventricles (arrows in Fig. 2.2b), although their appearance is smoother and more
continuous when the linear filter and/or post-average processing is used.

2.3.3

ROI analyses

Normalized measurements of SNR and CNR are presented in Figure 2.3. The non-linear
mask function results in a significantly larger SNR or CNR (P<0.05 for GP, P<0.01 for
periventricular veins, STN; P<0.001 for frontal WM, OR, RN). The frequency-based
scheme results in significantly larger CNR or SNR than both post-average and singleecho, except for GP where no significant difference is detected between post-average and
frequency-based processing, although both result in significantly larger CNR than singleecho. Specific P-values are presented for pair-wise comparisons of processing scheme in
Fig. 2.3.
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Figure 2.2 Minimum intensity projections through 4 mm at the basal ganglia for different
SWI post-processing schemes (first column: single-echo, second column: post-average,
third column: frequency-based) and mask functions (first row: linear mask, second row:
non-linear mask).
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Figure 2.3 CNR for GP (a), OR (b), periventricular veins (PVV) (c), STN (d), RN (e),
and SNR for frontal WM (f). Filled black circles: linear mask function; empty squares:
non-linear mask function. Points: mean; bars: standard error (n=10). Values have been
normalized by the mean value of the metric in linearly masked single-echo SWI.
Illustrated are significant P-values for pairwise comparison of post-processing schemes
(* P<0.05, ** P<0.01, *** P<0.001).
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2.3.4

Visual comparison

Mean ranks are presented (Figure 2.4) for qualitative impression of SNR of frontal WM,
and for visibility of various structures. For all paramagnetic perturbers (GP, STN, RN,
periventricular veins), the linear filter resulted in significantly (P<0.001) greater visibility
(equivalently, lower mean rank). The post-average scheme resulted in significantly lower
mean ranks than both frequency-based and single-echo schemes for these structures as
well – except periventricular veins, where there was no significant difference between
post-average and frequency-based processing. In contrast, for visibility of OR and SNR
of frontal WM, the non-linear filter was ranked as significantly better (P<0.001). For OR,
the frequency-based scheme was significantly better than both single-echo and postaverage schemes. Specific P-values are presented for pair-wise comparisons of
processing scheme in Fig. 2.4. Mean ranks of artifact severity are presented (Figure 2.5).
In general, the linear mask function results in less severe artifacts, (P<0.001); the postaverage scheme results in the least severe artifacts. Inter-rater agreement, as assessed by
interclass correlation coefficient, was excellent (frontal WM, 0.88; GP, 0.93; OR, 0.85;
periventricular veins, 0.82; STN, 0.91; RN, 0.93; artifacts, 0.96).

2.3.5

!!∗ measurements

Values of !!∗ are presented in Table 2.2 as measured in ROI’s placed in various
structures. For comparative purposes, values reported by Denk and Rauscher8, Perán et
al.14, and Gelman et al.15 are provided.
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Figure 2.4 Mean rank of visibility for GP (a), OR (b), periventricular veins (PVV) (c),
STN (d), RN (e), and mean rank of visual impression of signal to noise ratio for frontal
WM (f). Filled black circles: linear mask function; empty squares: non-linear mask
function. Points: median; bars: interquartile range (n=10). Illustrated are significant Pvalues for pairwise comparison of post-processing schemes (* P<0.05).
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Figure 2.5 Mean rank of artifact severity at sinuses. Filled black circles: linear mask
function; empty squares: non-linear mask function. Points: median; bars: interquartile
range (n=10). Illustrated are significant P-values for pairwise comparisons of postprocessing schemes
(* P<0.05, ** P<0.01).
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Table 2.2 !!∗ measurements
Literature Values
Denk and

Perán et al 2007

Gelman et al

!!∗ (s-1)

Rauscher 2010

19.2 ± 1.4

19.7 ± 1.1

18.48 ± 1.5

21.9 ± 1.7

13.9 ± 1.0

15.26 ± 2.1

13.30 ± 3.9

17.8 ± 2.1

OR

22.4 ± 2.3

21.1 ± 1.0

--

--

GP

37.7 ± 4.0

--

33.99 ± 3.7

37.8 ± 2.4

putamen

26.1 ± 4.9

27.1 ± 1.0

24.08 ± 2.2

26.1 ± 1.5

frontal WM
frontal grey
matter

1999a

Values shown are mean ± standard deviation.
a ∗
!! values presented in this column are calculated as the sum of !! and !!! reported by
Gelman et al. Standard deviations presented are root sum of squares of standard
deviations of !! and !!! .
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2.4

Discussion

This study presents a comparison of (i) different SWI processing schemes, and, (ii)
different mask functions, in terms of SWI image quality as assessed by ROI analysis and
visual rating.

2.4.1

SWI optimization

Our choice of m for implementation in human data was based on optimized values as
determined by radiologist raters. This is justified for several reasons: (i) in all cases, rateroptimized values fell within the range of optimal m predicted by simulation; (ii) raters
were instructed to consider the influence of m not only on veins but also on other
structures and noise; (iii) there was excellent inter-rater agreement; and (iv) radiologists
are the end-users of SWI. Our optimal m value for linearly masked single-echo (i.e.
conventional) SWI was 6. In contrast, conventional SWI is virtually always implemented
with m=4. This choice is influenced by a seminal SWI study12 where CNR vs m was
simulated for a comparable range of vein phases. As in our simulation, that study found
that a lower m is required for maximum CNR for increasingly large phase. Our raters
found a slightly larger value of m to be most suitable. As our optimizations involved
simulation and rating, they are more comprehensive than previous efforts. We have
endeavored to choose values of m that are suitable for optimal visibility of a range of
structures, however, if re-optimization is required for a specific application, it should be
performed by trained raters.
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2.4.2

In vivo data

For small veins, typical targets of SWI, ROI measurements in vivo agree with those
predicted by simulation: optimal CNR can be achieved with the non-linear mask
implemented with a frequency-based processing scheme. This conclusion can be
extended to CNR of paramagnetic perturbers in general. However, according to visual
assessment by trained raters, these same structures are most visible when SWI is
performed with the linear mask and post-average processing. This apparent contradiction
highlights a discrepancy between CNR and qualitative impression of visibility. While the
non-linear filter and frequency-based scheme might independently result in more
dramatic contrast (for example, at the edges of GP in Fig. 2.2f), they do not necessarily
increase the information content of the image compared to other implementations of
multi-echo SWI. Rather, their implementation can result in an image with harsher
contrast wherein more subtle structure is less apparent. Images appear ‘burnt-out’ when
contrast is too high, with little gradation in the greyscale, which was interpreted by raters
as potential loss of information. It appears that maximum contrast should not be the
exclusive target when optimizing visibility.
The non-linear mask function and frequency-based processing demonstrated best
performance with respect to frontal WM and OR, a diamagnetic perturber, as judged by
both quantitative measures in ROI analyses, and visual ranking. For both frontal WM and
OR, we do not expect the mean signal in an ROI to change after multiplication with the
described mask functions, given their zero or positive frequency, respectively. Therefore,
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the improved performance of non-linear mask function and frequency based processing
for frontal WM and OR can be attributed to the reduced noise introduced into the image
in these regions by these post-processing strategies, given the absence of changes in mean
signal or contrast.
One limitation of multi-echo SWI is increased scan time. Fewer echoes or reduced
coverage could be used to reduce scan time. Alternatively, if coverage were expanded to
allow imaging of the entire supratentorial brain, scan time would be on the order of 20
minutes. In addition to SWI, it is possible to obtain many contrasts from this acquisition,
including !!∗ maps, frequency maps, and quantitative susceptibility maps. Given the highyield nature of this acquisition, the parameters recommended here are not unreasonable in
a clinical setting.

2.4.3

!!∗ measurements

Measured values of !!∗ agree closely with previously reported values. In the case of the
GP as well as the putamen, the standard deviations we report are higher than in other
papers. This result does not reflect less precise measurements. !!∗ is approximately linear
to iron concentration6, which varies considerably with age in these structures16. Since this
study involved a range of ages, we expect a large variation in iron concentration in basal
ganglia structures and the corresponding values of !!∗ . In white matter and grey matter,
our values of standard deviations are intermediate to and smaller than, respectively,
previously reported values. Thus, our measurements of !!∗ have comparable accuracy and
precision to previously reported values.
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2.4.4

Field inhomogeneity artifacts

Multi-echo SWI processing, in particularly post-average, typically resulted in less severe
field inhomogeneity artifacts compared to single-echo SWI. Denk and Rauscher8 showed
that, by employing a filter width that varies with echo time, field inhomogeneity artifacts
could be reduced further in post-average processing while preserving contrast elsewhere
in the image. To limit the matrix of comparisons in the present study, we elected not to
investigate the effects of an adaptive filter, although we expect its use would result in
further reduction of these artifacts.

2.4.5

Prospective applications

Ultimately, our recommendation for SWI implementation depends on the desired
application and allowed time. Certainly, it is clear that any implementation of multi-echo
SWI results in superior images than single-echo SWI.
For radiological use, post-average processing and the linear filter are favored. Given its
favored performance for visualizing paramagnetic perturbers, this implementation of
multi-echo SWI seems especially well suited to the study of neurodegenerative diseases
in which iron deposition is implicated. In addition, this technique might have a role in the
study of traumatic brain injury, stroke, and other conditions where abnormalities in
vasculature or blood products are involved. One specific diagnostic application is
assessing the presence of veins within white matter lesions. At 7 T, this has been
demonstrated to be specific to multiple sclerosis17, however current techniques at 3 T lack
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the sensitivity to delineate such veins. Optimized multi-echo SWI holds promise for
reproducing these findings at clinical field strengths.
In this study, volunteers were free of pathology and raters were thus only able to evaluate
visibility of normal structure. It is possible that the high contrast, low noise properties of
either (or both) frequency-based processing and the non-linear filter may facilitate more
rapid detection of very subtle pathology such as microbleeds. Alternatively, while
frequency-based, non-linearly filtered SWI may be undesirable for radiological
assessment, such an image may be optimal for automated tasks where high contrast and
low noise would be favored such as STN segmentation for electrode targeting, computerbased delineation of veins, or registration tasks.

2.5

Conclusion

Linearly masked post-average SWI is the recommended implementation of multi-echo
SWI for radiological use; however, non-linearly masked frequency-based SWI may have
use in computer-based segmentation or registration. A discrepancy between measures of
CNR and subjective impressions of visibility was found, highlighting an important
caution for SWI optimization.
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3

Metrics of internal jugular vein anatomy obtainable from
time

of

flight

Applicability

to

magnetic
chronic

resonance

venography:

cerebrospinal

venous

insufficiency
3.1

Introduction

Recently, a role for structural and functional abnormalities of intra- and extra-cranial
veins in the pathogenesis of multiple sclerosis (MS) has been proposed1-3. This so-called
chronic cerebrospinal venous insufficiency (CCSVI) is reported to involve occlusion of
major veins, frequently one or both of the internal jugular veins (IJVs)3. CCSVI has
motivated some patients to seek out endovascular treatments, despite growing doubt that
CCSVI in MS exists at all4.
A diagnosis of CCSVI requires extra-cranial and trans-cranial color-coded Doppler
sonography5. These tools are foreign to the conventional study of MS. The vast majority
of imaging for the diagnosis and monitoring of MS involves MRI6. Doppler sonography
is well suited for visualizing and quantifying blood flow, and is relatively portable and
inexpensive compared to MRI, but obviously does not demonstrate central nervous
system lesions. For logistical reasons, the addition of an extensive sonography study is
generally not warranted for MS investigations. If however, imaging of the draining
cerebral veins is desired, MRI can instead be used to produce three-dimensional
venograms of high quality and is capable of determining the presence of structural
abnormalities7,8. Susceptibility weighted imaging (SWI) is capable of visualizing intra-
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cranial veins with sizes on the order of the voxel dimensions, but is not appropriate for
visualizing major intra- or extra-cranial veins. Alternatively, time-of-flight (TOF) MR
venography (MRV), which enjoys clinical acceptance for intra-cranial venography9 and
can be used for extra-cranial venography, does not require administration of a contrast
agent and is an acceptable addition to research protocols on the criteria of safety for
control subjects.
The objective of this study is to classify metrics of IJV anatomy (CSA) obtainable from
TOF venograms. Specifically, we present strategies for the measurement of these metrics,
as well as expected reproducibility in healthy subjects. The results are discussed in the
context of suitability of TOF MRV for the study of CCSVI in MS.

3.2
3.2.1

Methods

MR imaging

This study was approved by the institutional research ethics board. Informed written
consent was obtained from all participants. Nine healthy volunteers (6 females, mean
age±standard deviation = 25±7 years) with no history of neurological or vascular disease
were recruited. Volunteers were scanned on a 3T MR scanner (TIM Trio, Siemens
Medical Solutions, Erlangen, Germany) with a 12-channel head coil and 4-channel neck
coil. Two-dimensional MR venography was performed in the axial plane using the
following parameters: TR/TE = 39/4.99 ms; flip angle, 50º; slice thickness, 2 mm; gap, 0.4 mm; matrix, 640 x 303; field of view, 400 mm x 250 mm; number of slices, 110;
GRAPPA acceleration factor, 2. An inferior saturation slab was used to null arterial
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signal. This sequence was performed three times for each volunteer. Between scans,
volunteers were instructed to rotate their head and neck and then return to a comfortable
centerline position. This paradigm was employed to introduce variation between scans
similar to what might be observed in serial scans within a longitudinal study.

3.2.2

Measurements of CSA

Left and right IJVs were segmented in each slice using a semi-automated 2D regiongrowing tool in OsiriX version 3.9.4 32 bit (Geneva, Switzerland). Specifically, a seed
point was manually placed within the IJVs on each slice. Subsequently, a region of
interest containing all neighboring pixels with intensities greater than a user-defined
segmentation threshold was generated. The same threshold was used for all
segmentations.
Trends in CSA and its reproducibility were assessed at three positions of interest along
each IJV that were commonly observed in volunteers: (I) a local minimum in area near
the transverse process of the first cervical vertebra (C1), (II) a local maximum in area
where the common facial vein enters the IJV, and, (III) a local maximum in area at the
inferior bulb of the IJV. Positions were chosen independently for each volume; no
co-registration was performed. The average CSAs of the right and left IJVs were also
computed by taking the mean of CSA of all slices between the sigmoid sinus and either
the confluence of the IJV with the subclavian vein or wherever the IJV was obscured by
respiratory/flow motion. Intra-subject variation in CSA at each position of interest and in

78

average CSA on each side was quantified as the standard deviation (SD) and the
coefficient of variation (CV) of the three measurements for each volunteer.

3.2.3

Statistical analyses

Differences in left versus right IJV anatomy were assessed at the three positions of
interest and for the average area along the entire vessel. The mean values (across the
three acquisitions) of CSA at each position of interest as well as average CSA were
calculated for each volunteer. Subsequently, these four left-right pairs of metrics were
independently compared using the Wilcoxon signed-rank test. Statistical analyses were
performed in GraphPad Prism version 5.0 (GraphPad Software, La Jolla, California). A
two-sided P-value of 0.05 was deemed significant for all tests.

3.3

Results

A representative maximum intensity projection from a single volunteer is shown (Figure
3.1a). The three positions of interest in this study are clearly visible and are identified
with Roman numerals for the right IJV. Vascular signal is decreased in the inferior-most
slices, as is expected due to turbulent flow and respiratory motion. From the same
acquisition, representative axial images are presented In Fig. 3.1b (superior-most)
through Fig. 3.1d (inferior-most). The right IJV is clearly larger in caliber than the left.
At each of positions I, II, and III, arithmetic means and SDs of area measurements were
calculated for each volunteer (for left and right IJVs separately); CVs were calculated for
each subject at each position from those metrics as (SD)/(mean) x 100%. Additionally, in
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Figure 3.1 Representative time of flight venogram. Maximum intensity projection is
shown in (a), where the levels of the three positions interrogated in this study are
approximately identified with arrows. Position I is a minimum in cross sectional area
(CSA) near the first cervical vertebra (C1), position II is a local maximum in CSA at the
merge with the common facial vein, and position III is a local maximum in CSA at the
inferior bulb. Both internal jugular veins are visible in the representative axial slices in
(b) through (d). At the narrowing in the IJV near C1 shown in (b), the IJVs are
highlighted with arrows. In (c) and (d), the subject’s right IJV (on the reader’s left) is
visibly of larger caliber than the left.
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each subject, a single value (for each of left and right IJVs) of mean of average CSA was
measured as the mean of the three average CSA measurements, as was SD of these three
measurements and, subsequently, CV. As measured from these metrics in all volunteers,
grand mean CSA (mean of means) and root-mean-square (rms) SD and rms CV are
tabulated in Table 3.1 for left and right IJVs.

Table 3.1 Summary of IJV CSA metrics and reproducibility.
Left
Right
Position I
grand mean (mm2)

17.8

29.1

rms SD (mm2)

2.7

3.5

rms CV (%)

28

20

grand mean

75.1

98.1

rms SD

5.0

7.5

rms CV

7

8

grand mean

82.9

123.8

rms SD

4.0

8.2

rms CV

6

8

grand mean

44.9

66.8

rms SD

2.0

4.4

rms CV

5

7

Position II

Position III

Average CSA
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It is readily clear that these metrics of IJV CSA tend to be larger on the right than the left.
This trend was found to be significant for the average area (P=0.008) and for position III:
the local maximum at the facial vein (P=0.02). A trend was apparent at the other two
positions investigated: the local minimum near C1 (P=0.07) and the local maximum at
the inferior bulb (P=0.06).

3.4

Discussion

The objective of this study was to characterize metrics of IJV anatomy obtainable from
TOF MRV that might be used for evaluation of CCSVI in MS. Previous studies have
investigated the suitability of TOF MRV for CCSVI using qualitative scales that vary
from study to study. For example, in previous studies, IJVs have been dichotomously
classified as stenotic or normal10, rated from normal to severely narrowed on a 4-point
ordinal scale11, or categorized in terms of morphology12. This makes direct comparison of
results challenging. To our knowledge, ours is the first work to rigorously study a
quantitative metric (CSA) using a semi-automated area measurement tool. Advantages of
such an approach are that CSA is a continuous (as opposed to dichotomous or
categorical) variable, and logically one would anticipate such measurements to be
associated with less ambiguity, increased reproducibility, and less dependence on the
rater than previously implemented methods.
In general, we find that the right IJV is of consistently larger caliber than the left, in line
with previous studies13. It is imperative that future studies of CCSVI consider normal
left/right differences in order to avoid false positive for occlusion, especially on the left
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side. Additionally, a minimum near C1 is present in all volunteers. Indeed, we report a
grand mean CSA of the minimum near C1 of the left and right IJV to be approximately
20 mm2 and 30 mm2, the former being considerably smaller than the ostensibly
pathological CSA described by Zamboni and colleagues of 30 mm2 3. A recent study of
CCSVI in MS notes that as many as 78% of MS patients have IJV “stenosis” at the C1–2
level when interrogated with MRV11. That study did not have a control wing: the findings
of the present study imply this narrowing may in fact be normal, as was reported by
another recent study14.
While the volunteers in this study were free of pathological narrowing, the minimum in
CSA of the IJV near C1 can serve as a model of stenosis. At this position, we find that
the rms SD of CSA is on the order of 3 mm2. Stenosis of the IJV has been defined as
CSA less than 30 mm2 3: this is an order of magnitude larger than our expected
measurement error. Our observations favor a conclusion that TOF MRV is a sufficiently
reproducible method by which stenoses in CCSVI can be quantitatively studied without
resorting to an additional modality such as ultrasound. This conclusion is in line with a
previous study that finds TOF MRV to have modest image-reimage stability for
qualitative monitoring of morphologic features of the IJV15. In particular, measurements
of average CSA (i.e. along the entire vessel) are the most reproducible of all metrics
studied here (CV≤7%); classification of this metric in MS patients is required in the
future. Average CSA measurements have the additional benefit that no co-registration is
required to guarantee perfect alignment. Other authors have investigated the caliber of
IJVs after dividing the vessel into segments, for example, into lower, mid, and upper
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thirds16, or lower and upper halves10. While such an approach was not described in this
study, it is certainly possible given that we measure CSA for all slices of the IJVs. This
would simply involve defining segments to be studied, and averaging the CSA of all
slices within each segment.
To our knowledge, no previous studies have attempted to quantify intra-subject
reproducibility of IJV CSA measured with ultrasound, so a direct comparison between
modalities is not possible. However, at least three advantages of MRI over ultrasound are
noteworthy. First, CCSVI imaging with ultrasound requires extensive training5, the
absence of which can dramatically affect diagnostic outcomes17. Second, even mild
pressure exerted by the ultrasound probe inevitably alters the vein diameter, likely
leading to false-positive results14. Third, maximum intensity projections of MRV data
allow simultaneous visualization of the entire three-dimensional cervical venous
vasculature (ex. Fig. 3.1a).
Advantages of TOF over contrast enhanced MRV are two-fold: first, the former does not
require the administration of a contrast agent, making its use more acceptable in studies
involving a control wing; and second, in-plane resolutions of TOF MRV are typically
higher than for contrast enhanced MRV, allowing for more precise measurements of CSA
and more confident visualization of stenosis.
TOF MRV can be used to monitor morphological features of the cervical venous
vasculature, whereas both anatomy and flow are of interest in CCSVI. Additional studies
are required to identify an optimal MR strategy by which flow may be interrogated,
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although a recent study suggests a strong association between reductions in IJV caliber
and reductions in flow10.
Additional analyses of the potential dependence of CSA on acquisition parameters and
segmentation threshold would be useful. Despite this, the proposed methodology is well
suited for quantitative comparisons between patients and healthy controls, assuming the
same parameters, including segmentation threshold, are used for all groups.
This study was not without limitations. The paradigm employed to introduce variation
between serial scans – readjustment of head and neck – was relatively simple compared
to what might be expected between scans on separate days or separate scanners.
Additionally, a number of factors that were not accounted for might introduce variation in
caliber of IJVs, including hydration level, clothing, and how tightly the subject is packed
into the imaging coil. Ultimately, the present study classifies the contribution to CSA
variation due to measurement error. Comprehensive evaluations in a patient cohort of
scan-rescan stability of TOF MRV for measurement of IJV mean CSA are presented in
Chapter 4 of this thesis.

3.5

Conclusion

We find that TOF MRV can be used for robust quantitative assessments of IJV anatomy.
In healthy controls, we find that the right IJV is of larger caliber than the left, an
important consideration for CCSVI studies. A characteristic narrowing of the IJV near C1
is present in all volunteers and must not be confused with pathological stenosis in
patients. We recommend that these metrics of IJV anatomy, in particular average CSA,
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be classified in patients with MS in order to evaluate the presence of a structural substrate
for CCSVI.
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4

Increased deep grey matter iron is present in clinically
isolated syndromes
4.1

Introduction

In multiple sclerosis (MS), abnormal iron deposition within subcortical nuclei1 and at the
periphery of some white matter lesions2 has been known to exist for decades. However,
this evidence has been derived from cross-sectional imaging studies, or from ex vivo
work, and thus does not establish whether the observed iron accumulation was a cause or
consequence of pathology in MS.
The presence of iron in MS has generally been thought to be secondary to an
autoimmune response that either affected normal metabolism of brain iron3 or induced
extravasation of hemoglobin-containing red blood cells into the central nervous system
(CNS) parenchyma2. However, it has also been recognized that increased brain iron could
directly promote oxidative damage at many levels in the cell4. The disease stage at which
iron accumulation is detected might provide insight into iron’s role (or roles) in MS.
In this work, we performed quantitative MRI investigations of brain iron in patients with
a clinically isolated syndrome (CIS) who are at high risk of being diagnosed with MS in
order to determine if iron is present in early MS and if so, to determine its spatial
distribution. Using a well-validated surrogate MRI-derived metric of iron (the effective
transverse relaxation rate, !!∗ )5, we evaluated iron in the brains of CIS patients on a
voxel-by-voxel basis. For clusters of voxels where differences in !!∗ (and thus potentially
Reprinted from Multiple Sclerosis and Related Disorders, DOI: 10.1016/j.msard.2013/06/017, Quinn, MP,
Gati, JS, Klassen, LM, Lee, DH, Kremenchutzky, M, Menon, RS. Increased deep gray matter iron is
present in clinically isolated syndromes, ©2013, with permission from Elsevier.
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iron) were detected between groups, mean !!∗ was regressed against a number of disease
status-related parameters.
To further explore the observed increases in iron in deep grey matter in CIS, we
measured the caliber of the major extra-cranial veins. These vessels have been implicated
in a theory that proposes iron accumulation occurs in the brains of MS patients as a
consequence of abnormal venous drainage of the CNS6. According to this chronic
cerebrospinal venous insufficiency (CCSVI) theory, CNS iron, derived from extravasated
red blood cells, mediates damage as a potent chemo-attractant for pathogenic cellular
effectors. While an association of MS lesions with small venules has been observed since
the earliest descriptions of the disease7, the abnormal venous drainage theory lacks
independent verification. Using magnetic resonance venography (MRV) and offline
segmentation, we measured the mean cross-sectional areas (CSAs) of the internal jugular
veins (IJVs) in patients and healthy controls. Subsequent correlations between IJV CSA
and mean !!∗ in regions where significantly increased iron was detected allowed for
assessment of any association between increases in iron and IJV caliber.
Ultimately, the main focus of the present study – differences in brain iron between
healthy controls and patients with clinically isolated syndromes – need not be coupled
with the topic of CCSVI. Indeed, while the support for a pathogenic role for venous
abnormalities in MS becomes increasingly tenuous, the timeline of well-established iron
accumulation in MS remains an unresolved, yet important issue for addressing potentially
early pathological changes in MS patients.
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4.2
4.2.1

Materials and Methods

Subject recruitment

Twenty-two CIS patients were prospectively recruited from the MS clinic in the London
Health Sciences Centre. Inclusion criteria were: (1) a single clinical attack indicative of
risk for developing MS according to McDonald’s 2010 criteria8, (2) less than one year
from clinical presentation, (3) 18 to 50 years of age, (4) no contraindication for serial
MRI scanning, (5) ability to provide informed consent. Sixteen healthy controls were
recruited from the general population. Cohort demographics are provided (Table 4.1).
Informed, written consent was obtained from all study participants. This study was
approved by the Health Sciences Research Ethics Board of The University of Western
Ontario.
Table 4.1 Cohort demographics

n
Age [mean (SD)]
females
EDSS [median
(95% CI)]
Disease duration
[mean (SD)] days
a

Two-sided t-test
Fisher’s exact test

b

Controls

Patients

P

16

22

--

38.6 (7.6)

36.7 (7.6)

0.44a

13

17

1.00b

--

1.0 (0.0,1.125)

--

--

235 (183)

--
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4.2.2

MR imaging

All study participants were imaged on a 3T MRI system (TIM Trio, Siemens Medical
Solutions, Erlangen, Germany). Using a 32-channel head coil, the following contrasts
were acquired. Axial FLAIR: TE/TI/TR = 136/2850/15000 ms; voxel size = 1x1x3 mm3.
Axial T2-weighted turbo spin echo: TE/TR = 99/5100 ms; voxel size = 1x1x3 mm3. T1weighted (T1w) three-dimensional MPRAGE: TI/TE/TR = 900/6.9/2060 ms; voxel size =
0.5x0.5x1.0 mm3. Three-dimensional multi-echo gradient echo (GRE): TE1/∆TE/TR =
10/7/52 ms (6 echoes). Three GRE volumes were acquired, with approximately 15 to 20
mm of overlap between adjacent slabs, providing full brain coverage including the
cerebellum. With a 12-channel head coil and 4-channel neck coil, two-dimensional time
of flight (TOF) MRV was performed in the axial plane using the following parameters:
TE/TR = 5/50 ms; voxel size = 0.8x0.6x2.0 mm3; 0.4 mm overlap between slices; flip
angle = 50º. An inferior saturation slab was used to null arterial signal.

4.2.3

Multi-echo gradient echo processing

Image processing was performed in MATLAB (The Mathworks, Natwick, MA), FSL
(FMRIB, Oxford, UK), and OsiriX (Geneva, Switzerland).
To quantify iron, maps of !!∗ were calculated for each multi-echo gradient echo slab via a
voxel-wise curve fit to a single exponential decay curve. Mean magnitude from each
GRE slab was registered to the T1w volume using the FSL tool FLIRT. Registration
parameters were then applied to the !!∗ slabs. Co-registered !!∗ slabs were concatenated
by arithmetic averaging of overlapping voxels.

91

For each volunteer, the T1w volume was then registered to the MNI_152 1x1x1 mm3
template provided with FSL. These registration parameters were then applied to the
concatenated !!∗ volume. The !!∗ volume, now in the space of the template, was blurred
using a 3D Gaussian kernel (full-width at half maximum, 6 mm) and down sampled to
3x3x3 mm3.

4.2.4

Measurements of CSA

From the TOF volumes, the right and left IJVs were segmented in each slice using a
semi-automated region-growing tool in OsiriX, where a seed point was first placed within
the IJV. Subsequently, all neighbouring pixels with intensities greater than a user-defined
threshold (constant for all segmentations) were included in an ROI, the area of which was
reported. For each participant, mean CSA was calculated for both right and left IJVs
along their extent from the sigmoid sinus to the confluence of the IJV with the subclavian
vein, generally at the level of the first thoracic vertebra. Mean CSA of both right and left
IJVs were compared between patients and controls using two-sided t-tests or MannWhitney U test, depending on distribution of data as assessed with Shapiro-Wilk testing,
using SPSS version 20.0 (IBM, Armonk, NY). Since the two IJVs form a downstream
bifurcation from a common major draining cerebral vein, we combined the CSAs of the
two IJVs together as the best indicator of a venous return anomaly from the brain. To
establish the test-retest reproducibility of the CSA measurements, IJVs were segmented
and measured in MRVs from a follow-up scan, nominally 4 months later. Additionally,
correlations between right, left, and total CSA with EDSS and disease duration were
performed.
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4.2.5

Lesion segmentation

Lesions were segmented on FLAIR via seed-point-based semi-automated region growing,
as well as manually where the semi-automated method did not yield accurate borders.
FLAIR volumes were registered to the 1x1x1 mm3 template; these registration
parameters were applied to the lesion masks. Lesion masks were then blurred as above,
downsampled to 3x3x3 mm3 to be matched to the aforementioned !!∗ volumes. All values
in the blurred masks greater than a threshold of 0.05 (determined by visual inspection to
be suitable) were assigned as lesion.

4.2.6

Image-based general linear model (GLM) analysis

A modified age-adjusted t-test was performed for each voxel in the co-registered 3x3x3
mm3 !!∗ volumes between patients and controls as follows. The change in !!∗ with age
due to normal aging was estimated by linear regression of !!∗ against age in the healthy
control cohort. This effect was subsequently subtracted from all subjects. Specifically, in
a given subject, for each voxel, the rate of change of !!∗ with age (as estimated in all
healthy controls) was multiplied by the subject’s age. This value was then subtracted
from the measured value of !!∗ in that voxel to ‘adjust’ it for age. A two-sided t-test was
then performed for each voxel in the age-adjusted volumes. Data points coming from
lesions were excluded.
This is highly similar to what is done in an age-adjusted t-test (i.e. a t-test with age as a
covariate), except that the effect of the covariate was measured only on one study group
(healthy controls), not both groups. We felt this to be appropriate given that the rate of
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change of !!∗ with age in patients is possibly influenced by disease duration. Therefore,
the most reliable way to estimate the effect of age alone on !!∗ is to calculate the
covariate coefficients in healthy controls. A potential limitation of this methodology is
that we have a relatively small group of controls from which to estimate the coefficients;
however, we do have a relatively large and well-sampled range of ages (from early 20’s
to late 40’s), which is arguably of equal importance. In the future, this study’s
methodology will be extended to a larger group of subjects and we anticipate improved
accuracy of this method at such time.
Significant clusters were identified as groups of >10 edge-wise neighboring significant
voxels after controlling the false discovery rate at 10%. Anatomically similar clusters
were grouped to select ROIs. In patients, mean value of !!∗ in each group of clusters as
regressed against a number of parameters, including age, extended disability status scale
(EDSS), disease duration, and IJV CSA. For correlations involving non-normally
distributed parameters, as determined by Shapiro-Wilk testing, Spearman correlation was
used. Otherwise, Pearson correlation was employed.
After a mean clinical follow-up time of 11.2 months after recruitment into the study, 8
CIS patients had converted to MS. To investigate if !!∗ differences (potentially iron) at
baseline relate to subsequent conversion to clinically definite MS, mean age-adjusted !!∗
levels in the ROIs identified above were compared between healthy controls, patients
who had not yet converted from CIS, and patients who had converted to clinically
definite MS. Comparisons were made using a one-way ANOVA and Tukey post-hoc
testing.
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4.2.7

Lesion !!∗ analyses

Average lesion !!∗ was calculated for each patient using co-registered lesion masks and
!!∗ volumes at a resolution of 1x1x1 mm3, before blurring. Average lesion !!∗ was
correlated against the clinical/imaging parameters.

4.3
4.3.1

Results

!!∗ depends on age in the cortex, putamen, edge of lateral
ventricles

Representative slices are shown in the first column of Figure 4.1 of the results of agecorrelation, where regression coefficients are overlaid on the template. Expected trends
due to iron accumulation with age are seen: !!∗ increases with age in various cortical
areas, and at an increased rate in the putamen and red nucleus (arrows in Fig. 4.1c, d
respectively). Moreover, negative coefficients were found in significant clusters at the
lateral ventricles (arrows in Fig. 4.1b) and edge of the brain, consistent with age-related
atrophy as cerebrospinal fluid has a lower !!∗ than grey and white matter.

4.3.2

In patients, !!∗ is decreased in normal appearing white
matter (NAWM) and increased in deep grey matter and
cortical areas

In the second column of Fig. 4.1, clusters are shown at positions where the age-adjusted
difference in !!∗ between patients and controls was significant. Positive values indicate
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Figure 4.1 Representative results from voxel-wise age-adjusted t-tests. Coefficients for
age (a-d) as estimated in healthy controls reveal !!∗ increases with age in various cortices,
putamen, and red nuclei; as well, !!∗ decreases with age around the edges of the lateral
ventricles and brain. Age-adjusted differences between patients and controls are shown in
the second column (e-h), where lesions have been excluded. Patients have decreased !!∗ in
deep white matter as well as increased !!∗ in the bilateral thalamus (g), right pulvinar (g),
and some cortices, including the posterior cingulate (e). The color look-up table at left of
a and b applies to the first column. The color look-up table at the left of e and f applies to
the second column.
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increased !!∗ (putative iron) in patients. In some white matter regions, patients have
decreased !!∗ (arrows in Fig. 4.1e, f). The presence of clusters of reduced !!∗ in white
matter despite exclusion of lesions indicates these significant changes between patients
and controls are not due to classical demyelination alone. Moreover, patients have
increased !!∗ in the medial thalamus (arrows in Fig. 4.1g), in a region encompassing the
right pulvinar, and in the bilateral globus pallidus (arrowheads in Fig. 4.1g), and, while
not shown here, the right putamen. At several positions within cortical grey matter,
patients have significantly increased !!∗ , for example, within a significant cluster in the
posterior cingulate (arrowhead in Fig. 4.1e).

4.3.3

Mean CSA of the right IJV is reduced in patients compared
to controls

Metrics of mean IJV CSA are tabulated (Table 4.2) for controls and patients. No
differences between patients and controls were detected for the left IJV. The mean CSA
of the right IJV was significantly smaller for patients than controls. While not a
significant difference, there was a trend (P<0.10) for the total CSA to be smaller in
patients than in healthy controls. There were no significant correlations for any CSA
metric (right, left, or sum) with age (evaluated over patients and controls), EDSS, or
disease duration (evaluated over patients only). A Bland-Altman difference plot is shown
(Figure 4.2), pooled for all subjects, to establish test-retest stability of total CSA. Neither
the bias of the difference between baseline and follow-up measurements, nor the
correlation between axes is significantly different from zero, which suggests IJV CSA is
well reproducible.
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Table 4.2 Mean cross-sectional areas of internal jugular veins
Controls (n=16)

Patients (n=22)

Mean (SD) [mm2]

Mean (SD) [mm2]

Left

54.2 (27.8)

52.6 (25.0)

0.679a

Right

96.0 (31.5)

65.7 (28.6)

0.004

Total (sum)

148.5 (42.2)

123.3 (39.2)

0.066

P

Two sided t-test, except for a where Mann-Whitney U test was used.
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Figure 4.2 Bland-Altman difference plot of baseline and 4 month follow-up of total IJV
CSA, pooled for all subjects. The dashed horizontal lines represent the 95% confidence
intervals of the bias of the difference between the two measurements. This bias, as well
as the correlation between difference and average, is not significantly different from zero.
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4.3.4

Correlations of !!∗ differences with clinical and imaging
parameters

Anatomically similar significant clusters were grouped into categories, as presented
(Table 4.3). Mean !!∗ was measured for all such clusters within a category and
correlations with disease status parameters were made in patients. Significant P-values
and correlation coefficients are listed (Table 4.3). Of note, for no ROI was a significant
correlation with IJV CSA detected.

4.3.5

Baseline !!∗

levels do not differ between MS and

unconverted CIS
Figure 4.3 presents !!∗   values in the ROIs identified in Table 4.3, as measured at baseline,
for: healthy controls, unconverted CIS patients, and MS patients (i.e. patients who had
CIS at baseline and have since received a diagnosis of MS). In no case was there a
significant difference between CIS and MS patients; from visual inspection the
distribution of !!∗ values is highly similar for both patient groups for all ROIs
investigated.

4.3.6

Lesion !!∗ has no association with IJV CSA

Average lesion !!∗ was not significantly correlated with any parameter, including any IJV
CSA metric. Mean lesion !!∗ in patients was 15.4±2.0 s-1. No lesions had a bright rim on
!!∗ .
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Table 4.3 Mean !!! and correlations in various ROIs. Correlations of mean !!! with age and IJV CSA were evaluated with Pearson test,
correlations of mean !!! with EDSS and disease duration were performed with Spearman test. n.s., not-significant.
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Figure 4.3 Mean !!∗ at baseline for healthy controls (HC, n=16), CIS patients who have
not converted to MS (CIS, n=14), and MS patients (MS, n=8, i.e. those subjects who
were in the CIS group at baseline that have since received a diagnosis of clinically
definite MS). For ROIs identified previously: bilateral thalamus and right pulvinar (a),
bilateral globus pallidus (b), right putamen (c), cortical hotspots (d), and white matter
cool spots (e). Error bars denote standard deviations. All significant pairwise differences
are indicated: *, P<0.05; **, P<0.01, ***, P<0.001.
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4.4

Discussion

In this study, we evaluated brain iron in patients at high risk for a diagnosis of MS. With
our voxel-wise methodology, we were able to reproduce well-known findings regarding
iron accumulation with age9: specifically, iron increases in numerous sub-cortical nuclei,
and, at a lesser rate, in various cortical areas.
Previous 3T MRI studies have investigated differences in brain iron between patients
with CIS and controls with conflicting results. In the study of Khalil et al., patients with
MS had significantly increased !!∗ in the basal ganglia compared to both CIS patients and
controls, whereas no differences were detected between CIS patients and controls10. In
that study, comparisons between patients and controls were made for !!∗ measured in
ROIs which are large in volume compared to the voxel-wise analyses performed in the
present study. Thus, an exclusively ROI-based approach has inherently reduced
sensitivity to iron deposition that is limited to only a portion of a structure. In contrast,
Hagemeier at al. used a MRI phase-based measurement to quantify iron that is sensitive
to variations in iron content within a structure11. In that study, the authors found evidence
of increased iron in CIS patients compared to healthy controls in the pulvinar, putamen,
caudate, and total sub-cortical deep grey matter. A difference in ages of subjects in each
study might also account for the different results. Khalil et al. studied a cohort of CIS
patients of ages 33.7±10.3 years and a healthy control cohort of ages 36.7±13.7 years. In
contrast, in Hagemeier et al.’s study, the CIS patients (40.1±10.4 years) and healthy
controls (42.8±14 years) were older. One possibility is that, in CIS/MS, normal age-
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related accumulation of iron is accelerated so that a difference is only detected at an older
age.
Our results suggest that iron accumulation in deep grey matter nuclei including the
putamen, globus pallidus, pulvinar, and medial portion of the thalamus has occurred by
the earliest clinical stages of the disease. Whether iron accumulation preceded other
pathology, occurred immediately after inflammation began, or is ongoing at the time of
clinical presentation remains unknown; this question will benefit from longitudinal
studies. Iron in these structures is in keeping with known iron accumulation and
potentially related atrophy in clinically definite MS1,12,13. In particular, increased thalamic
iron may mediate damage4 and contribute to common clinical symptoms associated with
the thalamus that can be present early in the disease course, including fatigue14 and
cognitive decline15. Curiously, a recent study at 7 T, which used quantitative
susceptibility mapping to interrogate iron levels in CIS patients, found increased iron in
CIS16, but failed to reproduce the above-mentioned and well-accepted trends in iron
accumulation with age. None of these previous studies have investigated correlations
between !!∗ differences and IJV caliber.
Our finding of no differences in !!∗ between MS and unconverted CIS may suggest that
increased brain iron is a nonspecific finding of early demyelinating disease. This must be
interpreted with caution because the stratification is not perfect: likely some currently
unconverted CIS patients will be diagnosed with MS in the future. With longitudinal
follow-up of this patient cohort, we will have more accurate diagnosis for all patients;
such comparisons will be more telling at that time.
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We find that at some positions within the cortex, CIS patients have significantly
increased !!∗ , after age adjustment, compared to controls. This result may indicate that
cortical iron accumulation occurs in early MS. Such iron may be implicated with grey
matter lesions17 and is consistent with the growing notion that the cortex is not spared in
MS evolution18. As cortical changes in !!∗ were unanticipated, the study was not designed
to investigate the presence of cortical demyelination that might co-localize with putative
iron increases.
In the future, we intend to compare observed iron changes in patients to the magnitude of
healthy age-related increases in iron. This could be done by dividing significant
differences in !!∗ between patients and healthy controls by healthy rates of change of !!∗
with age. These rates were estimated in the present study from 16 healthy controls. The
observed rates (Fig. 4.1 a-d) were measured from a large and relatively well-sampled
range of ages and agree with well-known relationships of iron and atrophy with age in
different parts of the brain. Therefore we felt these values were sufficiently accurate for a
first order correction of !!∗ data prior to t-test (indeed, this is a standard process for ageadjusted t-tests). However, given that conversion of !!∗ differences into equivalent years
of ageing would involve a division by rate of change of !!∗ , it would be very sensitive to
noise/inaccuracies in the rate of change data. Increased recruitment into the present study
is anticipated in the future; this data will facilitate more robust correlations between !!∗
and age.
In this study, we detected positions in lesion-free white matter with significantly reduced
!!∗ in patients compared to controls. These regions are located in areas where WM lesions
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are commonly observed in MS patients. Previous studies have interpreted decreased
relaxation rates in the NAWM of MS brains as decreased myelin or iron content,
inflammation, glial proliferation, and/or axonal loss19. Such changes in NAWM may
precede development of lesions; however, as decreases in !!∗ are non-specific, further
work remains to be done to identify specific disease mechanisms responsible. For
example, it is even possible that iron is diffusely increased in these regions and other
factors changing !!∗ overwhelm the expected increase due to iron.
To evaluate a potential role for the extracranial venous system in the observed iron
increases, we measured the CSA of the IJVs. We found a difference between CIS patients
and controls in the mean CSA of the right IJV only. Mean CSA metrics obtained from
TOF MRV are operator independent and reproducible. It is well known that the right IJV
is generally of larger caliber than the left20,21 – this difference is less pronounced in
patients with CIS. Our finding of significant differences in IJV caliber between patients
and controls is consistent with a recent study that found that patients with clinically
definite MS have significantly flattened IJVs compared to controls22, although the
evaluation of vessel caliber in that study was based on subjective rating by blinded
radiologists. The authors of that study did not report differences for left and right IJVs
separately, so it is difficult to make a complete comparison. Ultimately, we must be
cautious when interpreting IJV flattening or reduction of CSA as this may represent:
reduced intraluminal pressure which fails to force the vessel to be round, improper IJV
development, or external (i.e. outside of IJV) source of vessel pinching/occlusion.
We did not directly interrogate flow, nor did we quantify CSA metrics for vessels other
than the IJVs; however, at least one of the IJVs is invariably involved in every potential
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CCSVI case23. Retrograde/turbulent flow may result in reduced signal intensity within the
vessel, but this does not necessarily translate to a reduction in CSA given the very high
and relatively uniform contrast that we found to be typical between IJVs and surrounding
tissue. If substantial flow abnormalities were present, then it is possible that a reduced
CSA would be measured due to reduction in signal intensity at the edge of a vessel where
such turbulence was present and this could fall below the segmentation threshold.
However, such abnormalities would also be associated with poor venous contrast and
ghosting or phase-encode artifacts; such artifacts are absent in the IJVs in our data. We
found the IJVs to be almost always very well demarcated with excellent contrast from
surrounding tissue in controls and patients alike. Therefore, our finding of reduced CSA
is most likely explained as reduction in the real CSA of the IJV; it is a remote possibility
that reduced CSA may be a consequence of highly turbulent/retrograde flow, given that
the artifacts that should accompany such flow disturbances are absent. Such artifacts are
notoriously variable from scan session to scan session whereas we have successfully
demonstrated that there is no significant scan-rescan variability in CSA metrics. Even if
there were a change in CSA introduced by turbulence or retrograde flow, our data show
that this is consistent over time. The lack of correlation between CSA and age suggests
that CSA is not a dynamically evolving property of the IJVs in adults. Moreover, CSA is
not related to conventional clinical metrics such as EDSS or disease duration.
To explore correlates of !!∗ changes in CIS, we performed a regression of !!∗ against
various potentially disease related parameters for patients for clusters where the ageadjusted difference in !!∗ between groups was significant. The positive correlation
between EDSS, a measure of clinical disability, and thalamic !!∗ suggests worsening
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clinical status with increased brain iron. This result is consistent with findings in definite
MS10. The observed negative correlation of cortical grey matter increases in !!∗ with age
might indicate patients with CIS are more susceptible to increased tissue loss or atrophy
at these positions with age, possibly due to iron-related oxidative stress. We found no
evidence that changes in IJV caliber are related to changes in !!∗ in any structure,
including putative iron accumulation in grey matter, or diffuse damage in NAWM.
White matter !!∗ is typically on the order of 20 s-1 24; however, in white matter lesions in
CIS, !!∗ was measured to be dramatically smaller, suggesting against significant intralesion iron in CIS. The lack of association between IJV CSA and lesion !!∗ also
contradicts vein-mediated deposition of iron in classical MS lesions. The absence of
bright lesion rims on !!∗ may indicate that iron arrives at these positions later in the
disease2.

4.5

Conclusion

In summary, we find that CIS patients have increased !!∗ , a putative metric of iron
deposition, in deep and cortical grey matter compared to controls. Damage to NAWM is
present in CIS, as indicated by reduction in !!∗ . These !!∗ changes may be nonspecific for
early demyelinating disease and of limited predictive value for future MS diagnosis:
future work is needed to confirm these hypotheses. Our observations confirm IJV
narrowing at the earliest stages of MS, but do not support a role for venous caliber
changes in explaining the increased iron deposition observed in CIS. Other events must
give rise to the detected changes in !!∗ .
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5

Central veins in white matter hyperintensities can be
detected at 3 T and may be predictive of an MS
diagnosis
5.1

Introduction

Demonstration of white matter lesions with magnetic resonance imaging (MRI) is central
to multiple sclerosis (MS) diagnosis1. However, white matter hyperintensities (WMHs)
are not specific to MS and may reflect a number of physiological processes other than
inflammatory demyelination (which is itself not specific to MS), including metabolic,
vascular, and neurodegenerative disorders2. Requirements for MS diagnosis include that
demyelinating lesions be proved as disseminated in space and time, moreover mimics of
MS must be excluded from the differential3. Ultimately, the process of diagnosing a
patient with MS can take months or years4.
An early and accurate diagnosis with MS will allow quality of life to be retained through
early initiation of disease-appropriate management5. To that end, there is a growing
interest in identifying biomarkers to facilitate discrimination between MS and non-MS at
first clinical presentation.
One such biomarker may be an MRI-detectable penetrating vein within a WMH. MS
lesions have been known to be venocentric since the earliest descriptions of the disease6.
It was not until 2000 that Tan and colleagues directly demonstrated this physiological
finding in vivo with MRI7. Interest in this biomarker has grown in subsequent years.
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In particular, several studies performed by the Nottingham group have addressed this
topic8-11, and have taken advantage of the excellent visibility of small veins achievable
with 7T MRI. In one study, they reported that all patients who converted from suspected
MS to clinically definite MS had >40% white matter lesions with central veins at
baseline11. It must be noted that 7T MRI is exclusively a research tool, with virtually no
prospect for clinical use in the near future. In clinical practice, 3T and more commonly
1.5T MRI systems are used; however at these lower field strengths, the visibility of veins
using conventional image contrasts is diminished and the practically of the proposed
biomarker remains unestablished. Our objectives in the present study are to determine
how well central veins in WMHs can be detected using our multi-echo SWI methodology
at 3T, and also to investigate the value of such MRI-detectable penetrating veins in
WMHs for predicting conversion from clinically isolated syndromes (CIS) to MS.

5.2
5.2.1

Methods

Subject recruitment

The same patient and control cohorts as in Chapter 4 of this thesis were studied. In short,
22 patients with a CIS suggestive of MS were recruited from the MS Clinic at the London
Health Sciences Centre. Additionally, 16 age- and sex-matched healthy controls were
recruited from the general population. Informed, written consent was obtained from all
study participants. The Health Sciences Research Ethics Board of The University of
Western Ontario approved this study.
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From a mean follow-up of 11.2 months, updated clinical statuses for all patients were
available, namely whether or not an MS diagnosis had been made.

5.2.2

MR imaging

All study participants were imaged on a 3T MRI system (TIM Trio, Siemens Medical
Solutions, Erlangen, Germany). Relevant contrasts acquired include 2D axial FLAIR:
TE/TI/TR = 136/2850/15000 ms; in-plane resolution = 1x1 mm2, 50 slices, slice
thickness = 3 mm. 3D T1-weighted (T1w) MPRAGE: TI/TE/TR = 900/6.9/2060 ms;
voxel size = 0.5x0.5x1.0 mm3. Additionally, 3D multi-echo gradient echo (GRE):
TE1/∆TE/TR = 10/7/52 ms (6 echoes), voxel size = 0.5x0.5x1.0 mm3. Three GRE
volumes were acquired, with approximately 15 to 20 mm of overlap between adjacent
slabs, providing full brain coverage including the cerebellum.

5.2.3

Image processing

Processing was performed in MATLAB (The MathWorks, Inc., Natwick, MA) and FSL
(FMRIB, Oxford, UK).
Magnitude and phase data from each GRE slab were combined to produce multi-echo
susceptibility weighted images (SWI) according to post-average processing with the
conventional, linear mask function as described in Chapter 2. From magnitude data, maps
of S0, the steady state signal, were generated via voxel-wise curve fit to Eq. 2.3.
Using transformation matrices calculated from co-registering mean magnitude for each
slab to the T1w volume (as in Chapter 4), SWI and S0 volumes were transformed into the
space of the corresponding T1w volume for that patient. The three registered slabs of
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each contrast for a given patient were concatenated by arithmetic averaging of
overlapping voxels. To remove T1-weighting and the effect of flip-angle variations over
the imaging slab from SWI, the S0 volume was first median-filtered with a 5x5x5 mm3
kernel to smooth and denoise the volume. The full-brain SWI volume was divided by the
filtered S0 volume to produce a full-brain SWI with consistent contrast throughout the
volume. Representative SWI images before and after correction with filtered S0 are
shown in Figure 5.1. FLAIR volumes were co-registered to T1w volumes using the
FLIRT tool from FSL.

5.2.4

Image analysis

SWI and FLAIR for each volunteer (patients and controls), as processed above, were
saved to a directory with a random label. All identifiers were removed to ensure image
rating was blinded. Vein rating was performed for one subject at a time, as follows.
FLAIR and SWI were loaded in FSLVIEW viewer, which allows volumes to be viewed
in the three orthogonal planes simultaneously. WMHs were identified on FLAIR; only
WMHs with a maximum dimension in one of the three orthogonal planes of at least 3 mm
were rated. FLAIR image was then toggled off to reveal the SWI image. The presence of
a central vein was then rated (yes or no) using the criteria proposed by Tallantyre9.
Venous vessels were hypointense on SWI and were only counted if they (i) could be
visualized in at least 2 perpendicular planes, (ii) appeared linear in at least 1 plane, and
(iii) were completely surrounded by hyperintense signal in at least 1 plane. The total
number of WMHs and the total number of venocentric WMHs were recorded for each
volunteer.
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Figure 5.1 Multi-echo SWI images before (a-c) and after (d-f) correction by division with
blurred S0. Unwanted effects of non-uniform flip angle, T1-weighting, and receive coil
sensitivity are mitigated using this methodology.

116

We acknowledge that the number and distribution of WMHs in a given subject had the
potential to unblind the primary rater in this study with respect to subject status (patient
versus control). We evaluated this possibility as follows. Thirteen lesions from different
subjects were cropped from surrounding tissue. A secondary rater, blinded to the original
rating results, was shown these cropped lesions one at a time and asked to rate for a
central vein. As a measure of inter-rater agreement, Cohen’s kappa was calculated to be
0.70, indicating adequate agreement. For future work, we propose rating by consensus of
two physicians to improve inter-rater agreement.

5.2.5

Statistical evaluation

All statistical analyses were performed in Prism v. 5.0 (GraphPad, LaJolla, CA).
Using Fisher’s exact test, WMH counts (venocentric versus non-venocentric) were
compared between healthy controls and all CIS patients. Using Chi-squared, WMH
counts were compared between healthy controls, CIS patients who did not convert to MS
by follow-up, and CIS patients who did convert to MS by follow-up. Post-hoc
comparisons were made between pairs of columns using Fisher’s exact test with HolmBonferroni correction of P-values.
For each subject, the %LCV (percentage lesions with central veins) was calculated as
(number of WMHs with a central vein)/(total number of WMHs)x100%. Using two-sided
t-test, %LCV was compared between healthy controls and all CIS patients. Using oneway ANOVA with Tukey post hoc, %LCV was compared between healthy controls, CIS
patients who did not convert to MS by follow-up, and CIS patients who did convert to
MS by follow-up.
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5.3

Results

Representative FLAIR and SWI images are shown for a venocentric WMH in Figure
5.2a,b and for a non-venocentric WMH in Fig. 5.2c,d. Despite similar appearance on
FLAIR, a radiological standard for lesion identification, there is a differential appearance
on SWI.
By the follow-up, 8 patients had been diagnosed with MS. These patients make up the
MS group referred to subsequently; all other patients comprise the non-converted CIS
group. Group totals of WMHs with and without central veins are presented (Table 5.1).
In the MS group, 67% of all lesions were venocentric; in non-converted CIS, 50% of
lesions were venocentric; in the healthy control group, 24% of WMHs were venocentric.
In the entire baseline CIS group, of 288 lesions, 59% were venocentric. When comparing
WMH venocentricity counts in healthy controls to all CIS patients, Fisher’s test yields
P=0.0003. When considering all three groups separately, the Chi-square test yielded a
highly significant P<0.0001. P-values from post-hoc pair-wise comparisons, corrected for
multiple comparisons, were: between healthy controls and non-converted CIS, P=0.013;
between healthy controls and MS, P<0.001; and between non-converted CIS and MS,
P=0.011.
Means and standard deviations of %LCV were calculated for healthy controls (12±19%,
n=8) and all patients with CIS at baseline (55±33%, n=20) and compared with a t-test,
yielding P=0.002. Figure 5.3 presents %LCV for each subject: healthy controls,
unconverted CIS, and MS patients (ANOVA P=0.0004, post hoc significant pairwise
differences illustrated).
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Figure 5.2 FLAIR (a,c) and multi-echo SWI (b,d) of a venocentric WMH in a patient
with MS (a,b) and of a non-venocentric WMH (c,d) in a healthy control.
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Table 5.1 Contingency table of WMH counts in healthy controls and patients.
Healthy

Non-converted

Controls

CIS

Venocentric WMHs

7

65

106

Non-venocentric WMHs

22

64

53

MS

120

P<0.05
P<0.001
100

%LCV

80
60
40
20
0
HC

Non-Converted CIS

MS

Figure 5.3 %LCV for different study groups. Patients with diagnosed MS show a
substantial increase in %LCV compared to both other groups. The dashed line indicates
%LCV of 40%, proposed to allow discrimination between MS and non-MS. All subjects
with no WMHs (8 controls, 2 non-converted CIS) were excluded from this analysis.
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5.4

Discussion

In this study, we investigated a newly proposed biomarker for MS – MRI detectable
veins within white matter lesions – using post-average multi-echo SWI with a linear
mask function at 3 T, as optimized in Chapter 2. We are able to detect such veins using
our methodology and differentiate between WMHs with and without central veins (Fig.
5.2). This study did not include imaging at 7 T, thus it is impossible to directly compare
our sensitivity to small veins using 3 T versus 7 T, but given the similarity of our results
to previous work at 7 T, as will be elaborated on below, we are confident our sensitivity
is similar.
When comparing the number of WMHs with and without central veins between study
groups, it is clear that we are able to detect significantly more WMHs with central veins
in patients with MS, as compared to both unconverted CIS patients and to healthy
controls. Various studies at 7 T have reported that in MS patients, the fraction of lesions
with central veins ranges from 59%12 to 92%13. Our detected incidence of central veins
within MS lesions (67%) appears to be at the lower end of this range.
Given the intimate role of a central vein in the development of a lesion in MS (Chapter 1,
Section 1.1.5), it is not unreasonable to expect all MS plaques to be associated with
central veins. Indeed, by use of SWI post-contrast injection, Tan et al. demonstrated
central veins in 99% of MS lesions7. Measurements of %LCV<100% in MS are likely
due to failure to visualize a certain fraction of veins, perhaps those that fall below the
detection threshold due to size, orientation, or oxygenation.
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There is a significantly larger fraction of lesions that are venocentric in the non-converted
CIS group compared to healthy controls (50% versus 24%). This suggests either (1)
several MS patients remain in the non-converted CIS group who have yet to be
diagnosed, (2) venocentric lesions are a feature of other diseases which might be
indistinguishable from MS at early clinical presentations, or (3) both of the above.
According to the literature, WMHs in individuals in the healthy control cohort may be
associated with relatively benign pathology such as high blood pressure14 or headache15,
neither of which are necessarily associated with venocentric pathology. Alternatively,
these WMHs may be idiopathic and without clinical manifestation. Healthy controls
included in this study had relatively few WMHs (median: 2, min: 1, max: 7) but it is not
unrealistic that these foci could occasionally be associated with a vein merely ‘by chance’
given the ubiquitous nature of veins in the brain.
When evaluating %LCV on a subject by subject basis (Fig. 5.3) we are able to reproduce
the 7T finding of Tallantyre et al. that all patients with MS have %LCV>40% at
baseline10. This reinforces speculation that detection of this biomarker at first clinical
presentation may have utility in expediting MS diagnosis. Due to the relatively short
study window (less than 1 year, although patients will continue to be followed until 2
years) it is likely that some CIS patients who have not yet received an MS diagnosis will
eventually receive one. In fact, the non-converted CIS group shows a bi-modal tendency,
with one cluster of patients (%LCV>40%) having %LCV distinctly larger than the other
cluster (%LCV<40%). An interesting hypothesis that awaits confirmation at the study’s
completion is that those non-converted CIS patients in the upper cluster will eventually
be diagnosed with MS, and those in the lower cluster will not. Given the short follow-up,
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and the fact that we expect many non-converted CIS patients to yet receive an MS
diagnosis, at this time calculation of positive and negative predictive values is
inappropriate.
A single other 3T study has also reported that venocentric lesions in possible MS are
predictive of subsequent MS diagnosis16. That study used single-echo SWI (potentially a
more practical approach, as discussed below). The authors, however, did not report
fraction of lesions that were venocentric; rather, they reported the total number of large
lesions with penetrating veins for each patient. This rating methodology may not be
useful in radiological presentations with numerous small foci.
One significant limitation of the present study is the choice of MRI contrast for vein
detection. As implemented here, multi-echo SWI requires approximately 32 minutes for
full brain coverage. This is prohibitively long for clinical use. We did not investigate the
ability of multi-echo SWI with fewer echoes, or single-echo SWI (both of which require
reduced scan time) to visualize intra-lesional veins. Given the increasing prevalence of
3T systems in clinical use (both in developed and developing countries), investigating the
feasibility of imaging this biomarker at 1.5 T may be a less important goal than
optimization at 3 T, given the increased venous contrast at the latter field.
Moreover, as alluded to previously, the specificity of this biomarker to MS remains
unestablished. Certainly, not all CIS patients have MS17. The prospective value of this
biomarker might be diminished if large values of %LCV are also detected in common
MS mimics. To partially address this question, we are currently recruiting patients with
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WMH who have clinical diagnoses other than MS to serve as a control group for the
same type of analyses described herein.
Two notable challenges for all scientists working in this field remain. The first: what to
do in the case of patients with very small or large lesion burdens? In the first case, what is
the minimum number of lesions that must be rated (and therefore be present) to obtain a
confident evaluation? In this study, we had 2 patients with no WMHs. In the second case,
might it be appropriate to rate only a subset of the lesions in order to obtain a
representative but accurate %LCV? Using hypergeometric distribution methodology,
Tallantyre et al. report that if only 10 lesions per patient were rated (in patients with >10
lesions), the diagnosis of MS/non-MS could correctly be predicted with 90% certainty in
44 out of 45 patients tested10.
The second challenge is: what constitutes a penetrating vein from a radiological
standpoint? The shape of the lesion, and possibly the course of the vein within are
relevant. In several studies, criteria for venocentricity are clearly and unambiguously
outlined; in others, they are absent. It would be best to adopt a common set of criteria,
such as those used herein and originally outlined in the works of the Nottingham group9.

5.5

Conclusion

We report that WMHs with penetrating veins can be detected in MS using multi-echo
SWI at 3 T. A larger fraction of venocentric WMHs were detected in MS (67%)
compared to non-converted CIS patients (50%), and healthy controls (24%). Our
sensitivity to central veins appears to be in line with that of higher field systems.
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Preliminary results in a cohort of CIS patients that are being followed serially are
consistent with previous reports that a large %LCV at baseline is highly predictive of a
subsequent MS diagnosis.
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6

Conclusion

In this thesis, we have proposed and developed methodology that has allowed subtle
components of multiple sclerosis pathology to be probed with MRI, especially in regard
to iron accumulation and a role for veins. To implement this methodology in the context
of early MS, we have recruited a cohort of patients with clinically isolated syndromes
(CIS) as well as healthy controls; we are currently following these cohorts longitudinally
with scans every 4 months over a 2-year period. This chapter provides a brief summary
and discussion of experiments described in this thesis. Possible extensions of this study
and methodology are discussed.

6.1

Thesis Summary and Discussion

For decades, an association has been recognized between MS and iron accumulation in
deep grey matter nuclei1 as well as focally within lesions2. Questions posed about iron’s
role as either a mediator of damage or as an epiphenomenon remain unanswered3. In this
thesis, we sought to characterize biomarkers associated with iron deposition in patients
with early presentations of MS.
Chapter 2 addressed Specific Aim 1: to optimize an MRI post-processing technique to
produce both cerebral venograms and quantitative images for measuring iron. In this
regard, we established an optimal method to perform multi-echo susceptibility weighted
imaging (SWI), a qualitative contrast that yields excellent visibility of small veins and
iron-rich structure. Such a contrast holds promise for investigating changes in early MS,
given the established, yet incompletely understood link between small veins, iron
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accumulation, and the disease. In addition to the above-mentioned central objective of the
chapter, we demonstrated that numerical simulation and scoring by trained raters are not
equivalent in terms of optimization of contrast for SWI. One particularly promising
application of this technique to which we are looking forward is the study of central veins
within white matter hyperintensities in MS (as described in Chapter 5) versus in other
neurological conditions. Moreover, the advantage of a multi-echo gradient echo sequence
is that such data facilitate computation of maps of !!∗ , a quantitative parameter which is
highly sensitive to iron levels in the brain4 (as used in Chapter 4). In this chapter, we also
validated our measurements of !!∗ against numerous previously reported values.
Chapter 3 addressed Specific Aim 2: to establish reproducibility of quantitative
measures of internal jugular vein (IJV) caliber, given the proposed role for these veins in
MS pathogenesis. Inasmuch, we proposed methodology to obtain quantitative metrics of
IJV caliber from axial time of flight magnetic resonance venograms. We established that
these metrics are sufficiently reproducible to allow the anatomy of these veins to be
described in a quantitative manner. We report coefficient of variation of measurements of
average CSA along the entire vessel to have typical values on the order of 7%; this is our
motivation for using this metric in Chapter 4.
Chapter 4 addressed Specific Aim 3: to compare relative levels of iron between CIS
patients and healthy controls. We applied above methodology to study differences in iron
that potentially manifest early in MS by comparing !!∗ for each voxel in the brain
between healthy controls and patients with CIS. Evidence for increased iron was found in
deep as well as cortical grey matter. Increased thalamic iron was associated with clinical
disability, suggesting that iron may cause tissue damage; alternatively, iron deposition
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may occur as a possibly quiescent epiphenomenon very soon after the primary pathology.
With future work, we intend to track iron levels in deep brain structures over time to
differentiate between the two scenarios. If initially high iron levels are responsible for
toxicity, they may not increase. If iron accumulation is a side-effect of an ongoing (and
possibly immune-related) process throughout the disease, then we expect iron levels to
increase with time. Of course, a dual role for iron is possible – as both a cause and
consequence of pathology. Our preliminary finding that iron levels at CIS may not
necessarily be predictive of subsequent MS diagnosis is very intriguing and requires
additional clinical diagnoses for our unconverted CIS cohort before confirmation.
Perhaps increased brain iron is typical early on in several idiopathic demyelinating
diseases, whereas MS is additionally marked by iron accumulation throughout the
disease? At the very least, our current findings, including correlation between deep grey
matter iron and clinical status, serve as a reminder that MS is a disease that extends
beyond the white matter and includes factors in addition to inflammatory demyelination.
In white matter, we did not detect increased !!∗ at lesion rims, a correlate of increased
iron at these positions5 that is known from histology. Beyond that, we are limited in our
ability to comment on the presence of lesion iron. We detected decreased !!∗ within
lesions. In MS tissue, we expect increases in R2* to be specific for increased iron, while
acknowledging many factors can contribute to a decrease in R2* (even in the presence of
increased iron) including demyelination and edema. Following longitudinal studies and
use of different quantitative contrasts (such as local frequency), we will be able to
comment on intra-lesion iron as a function of time.
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Taking our findings in deep grey matter and white matter lesions together, a possible
scenario emerges where iron in at least two compartments (deep grey matter and lesion)
accumulates differentially throughout the disease and thus may reflect different
contributions to tissue damage.
To explore one possible explanation of iron increases in the deep brain, we measured the
calibers of the IJVs. We found that the right IJV was significantly narrower in patients
than in healthy controls and the total IJV CSA (i.e. summed across left and right IJVs)
trended towards being lower in patients. This finding will need to be explored in the
context of longitudinal data for robustness. One important findings is that, after
regression between !!∗ increases and total IJV CSA, we found no evidence that these iron
increases were a function of IJV caliber, suggesting another disease mechanism must be
responsible for iron accumulation at these positions. In summary, increased iron is
present in early clinical stages of MS, but this is not due to vessel occlusion. Venous
abnormalities may exist in MS, but appear not to be functionally related to pathogenesis.
While CIS represents a relatively early point in the clinical disease course (ex. relative to
RRMS or SPMS), there is likely a window of a finite length of time between onset of
CNS inflammation and CIS. Information about iron concentration in affected tissue
during this window would be highly useful for elucidating iron’s role in MS. In the
future, insights into this problem may be acquired via imaging studies in groups of
individuals at high risk for developing MS or in appropriate animal models.
In the studies described herein, we did not use quantitative susceptibility mapping
(QSM), a relatively new technique for quantitative brain imaging6, although a brief

131

discussion is warranted here. In a quantitative susceptibility map, which is derived from
phase data, voxel intensity scales with local magnetic susceptibility, an intrinsic property
of the tissue (unlike !!∗ ). Like !!∗ , tissue susceptibility scales linearly with iron
concentration7 and is strongly influenced by myelin content8. An advantage of QSM is
that these images can be generated from a single gradient echo, although multi-echo GRE
can also be used. Using QSM, at least two studies have reported on increases in iron in
CIS compared to healthy controls by taking mean values in relatively large ROIs9,10.
These results suggest that QSM is more sensitive to iron than !!∗ , as a previous study
using the ROI approach with !!∗ failed to detect any difference between CIS and
controls11. However, an inherent problem with using QSM for the study of iron is that in
the presence of high iron concentrations, the signal-to-noise ratio in the phase image will
be reduced. This might lead to unreliable estimates of tissue susceptibility at these
positions.
A major challenge with QSM is the extensive post-processing, errors in which can lead to
image artifacts. In brief, a local frequency map is generated by unwrapping phase and
then filtering the unwrapped phase to remove background field contributions. Since a
very robust frequency map is required to create QSM of acceptable quality, homodyne
filtering is not sufficient. Instead, filtering is performed using more sophisticated
models6,12. Subsequently, this filtered and unwrapped phase is scaled to create a local
frequency map. The Fourier transform of this frequency map is divided by a dipole kernel
to produce the (Fourier transform) of the quantitative susceptibility map. This last step,
the field-to-source inversion, in particular is challenging as for some positions in Fourier
space, the kernel is equal to zero; therefore, the inversion is ill-posed and a solution
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cannot be found. A number of techniques have been proposed to overcome this
challenge, and can be found in the literature13.
QSM has also been used to study white matter fiber tracts by considering myelin as an
anisotropic perturber of magnetic field14, as opposed to a magnetic dipole (such as
punctate iron). While this is an area of ongoing research and optimization, this speaks to
the potential of QSM to study both myelin and iron.
In our studies, we did not use QSM for two major reasons. First, our phase data included
open-ended fringe lines15, a phase artifact that is the result of sub-optimal combination of
data from different receiver elements in the RF coil. In the presence of open-ended fringe
lines, all phase unwrapping algorithms currently used for QSM do not produce an
acceptable result. For SWI, unwrapping and filtering are performed automatically and
simultaneously by the homodyne method; although, as pointed out above, this type of
phase filtering is insufficient for QSM. Without properly unwrapped phase maps, QSM
cannot be performed. Second, at the onset of the study, optimization of QSM was in its
infancy and robust validations of a linear relationship between QSM and iron
concentration were absent. Therefore, our MRI protocol was designed with the goal of
generating !!∗ , which remains a widely used marker for iron, even alongside QSM8.
Indeed, if the phase unwrapping challenge can be overcome in the future, we anticipate
performing QSM in addition to relaxometry to study changes in iron and myelin in early
MS.
Chapter 5 addressed Specific Aim 4: to determine if venules can be detected within
lesions in CIS patients. We used optimized multi-echo SWI (Chapter 2) to interrogate the
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presence of central venules in white matter hyperintensities (WMHs). We find that
patients who have converted from CIS to MS had, at baseline, a significantly larger
fraction of WMHs with central veins compared to non-converted CIS patients, as well as
to healthy controls. More significantly, we also found that all patients who had been
diagnosed with MS within the (relatively short) study window had, at baseline, >40%
lesions with central veins. This supports previous work suggesting this biomarker could
be used to predict MS diagnosis at first clinical presentation16. Challenges remain when
considering the clinical feasibility this biomarker, including studying its specificity for
MS lesions, adoption of standard sequences and rating schemes, and large sample size
validation.

6.2

Future Work

The CIS and healthy control cohorts described in Chapters 4 and 5 are part of an ongoing
study, where all subjects are imaged every 4 months over a 2-year window. One strength
of our experimental design is that, by the end of the study, we will have reasonable
confidence in terms of an MS diagnosis of each CIS patient. This will facilitate
comparisons not between only patients and controls, but also between healthy controls,
patients who had MS at baseline, and those who did not. Ultimately, this will allow us to
increase the specificity of our analyses and make conclusions about the predictive value
at CIS of different metrics and factors for conversion to MS. The following are specific
experiments we intend to perform using this longitudinal data.
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6.2.1

Longitudinal study of deep grey matter iron

In Chapter 4 of this thesis, we compared !!∗ between all patients and healthy controls in a
cross-sectional manner (i.e. at study baseline). By the study’s conclusion, we will be able
to evaluate temporal changes including rates of change of !!∗ (either for each voxel in the
brain or for specific structures). An interesting question would be: do patients with early
MS demonstrate increased rates of iron accumulation compare to healthy controls, or are
local concentrations of iron relatively constant in time during this phase of the disease?
Phrased alternatively, we know there are differences in the intercepts of plots of iron
versus time for CIS patients and controls; are there also differences in the slopes?
Increased iron at baseline in MS compared to healthy controls is required if (but does not
necessarily indicate that) iron is a primary cause of damage to deep grey matter structure.
Alternatively, accumulation of iron with time might favour iron’s role as one of an
epiphenomenon of disease11. Only after both possibilities have been thoroughly vetted on
the entire study cohort will we be able to draw useful conclusions.

6.2.2

Longitudinal study of lesion iron and microstructure

The exact pathogenic mechanism of plaque development (including any role for iron)
remains unknown. One possibility is that the neuro auto-antigen for unknown reasons
(potentially related to environmental or genetic factors) stimulates an immune response
that results in irregular iron metabolism17. In this case, increased iron may only be
detectable after it has been sequestered by macrophages later in the lesion’s lifetime18.
Alternatively, increased iron may be detectable in the earliest stages of lesion
pathogenesis as an immediate result of increased iron transport19 or microhemorrhage2. It
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is unknown whether iron is directly responsible for inflammation and attraction of
cellular effectors, as proposed by Zamboni20, although if iron is a driving force for
damage, it should be present early in the lesion’s development. With our longitudinal
study data, we intend to perform retrospective and prospective analyses of lesions to
determine the spatial and temporal patterns of lesion iron via !!∗ measurements. In the
literature, it has been reported that as many as one quarter of white matter lesions in
CDMS have a hypointense rim on gradient echo magnitude images (corresponding with
increased !!∗ ) indicative of iron21. One study suggested that such iron accumulation
patterns are exclusive to the subset of lesions that are chronically active18. In our CIS
patients, no such signal changes at any lesions’ rims were seen at baseline. This is
consistent with iron accumulating at the lesion rim later in the disease; however after
quantitative analyses of serial data for many lesions we will have a more complete
picture.
Recently, it has been proposed that local frequency (an additional quantitative contrast
attainable from gradient echo images) is very sensitive to changes in tissue
microstructure, including changes in myelin and axons, during the progression of lesion
pathology in MS22, and could be used to estimate the activity within the lesion. This
hypothesis has only been explored through numerical simulation, as well as crosssectionally in vivo. The longitudinal nature of our data set will eventually facilitate
tracking of intra-lesional signal changes over time on a lesion-by-lesion basis, which will
allow us to study both lesion microstructure, and as noted above, iron.
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6.2.3

Study of venocentricity of white matter lesions

From the earliest descriptions of MS, the venocentric characteristic of plaques was
noted23. A central venule is certainly involved in the inflammatory machinery of the
plaque2, including iron deposition. Recently, numerous MRI studies16,24,25 have proposed
this finding might be non-invasively detected as a prospective biomarker for MS. We
explored this issue in Chapter 5, in a proof-of-principle experiment.
Given the prospective nature of our cohort, and increased recruitment that is anticipated,
we plan on extending the preliminary work presented in Chapter 5 of this thesis with
respect to a role for venocentric lesions in predicting conversion to MS. While the study
presented in Chapter 5 was limited by low sample size, we aim to recruit until a total of
30 to 50 CIS patients. By the study’s conclusion, we will be able to determine with
confidence if a high percentage of lesions with central veins at baseline is predictive of
subsequent MS diagnosis; our preliminary work suggests this is the case. Two recent
studies have reported on iron at the lesion rim in MS compared to other conditions, as
indicated by hypointense signal on !!∗ weighted MRI at the edge of the lesion21,26.
Perhaps the coincidental findings of increased iron and a central vein would improve
specificity of this methodology.
Given that white matter hyperintensities on T2-weighted MRI are notoriously nonspecific, one aspect of MS diagnosis for which this methodology would be highly useful
is differentiating MS from other neurological diseases on the basis of lesions with central
veins. Very few studies have investigated the presence of central veins in white matter
lesions of other diseases. Sinnecker and colleagues showed that in neuromyelitis optica
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spectrum disorders (which involve inflammatory demyelination and can be confused with
MS) only 35% of WMHs had a central vein, as opposed to 92% in MS21. This result
suggests the approach explored in Chapter 5 has potential to differentiate between the
two. Alternatively, Lummel et al. reported WMHs in patients with small vessel disease
were as often found along small veins as in MS (78% versus 80%)27. Certainly, work
remains to be done to establish in which diseases, if any, venocentric WMHs are
expected in addition to MS.
To further investigate these topics, we are recruiting an additional cohort of patients for
our study: patients with clinical diagnoses of neurological diseases other than MS but
with similar white matter hyperintensities (migraine, neurological presentations of
systemic autoimmune diseases, vascular disorders). We intend to recruit 20 patients in
this category that are age- and sex- matched to our control and CIS cohorts for a single
MRI using our 3T protocol. A revision to our ethics protocol has recently been submitted
to this effect.
The addition of this non-MS patient group will allow us to probe the specificity of
venocentric lesions, and potentially iron-containing lesions, to MS. Moreover, this new
group can serve as an alternative control when evaluating, for example, deep brain iron
levels or IJV CSA in MS. This will allow us to address additional relevant questions: Are
increases in iron, or changes in vein caliber (as detected in Chapter 4) specific to MS, or
prevalent in other neurologic disease as well?
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6.2.4

Longitudinal study of IJV caliber

In Chapter 4, we reported that the right IJV was of significantly reduced mean CSA in
CIS patients than in healthy controls, while no significant differences were found for the
left IJV, or sum of means. Following IJV CSA longitudinally in our complete cohort will
establish whether this difference is truly robust and if it is limited to MS, or if it is present
in other neurological conditions. This methodology will also allow us to examine the
possibility that IJV CSA is a dynamic property in MS (reflecting adaptive venous return).

6.3

In closing

The central objective of this thesis was to characterize MRI biomarkers associated with
iron deposition in patients with early presentations of MS; major findings in this regard
are summarized here. We found that metrics of brain iron were increased in CIS patients,
a cohort which included several early MS cases. While increased iron in MS is well
known, the predictive value of increased iron in CIS of a future MS diagnosis remains
unclear. Moreover, while IJVs were of reduced caliber in CIS patients, this was not
associated with metrics of iron accumulation, suggesting that another mechanism must be
responsible for iron deposition. Finally, we have reproduced ultra high field strength
findings that small veins can be detected within MS plaques, suggesting that there may be
diagnostic value in classifying the fraction of lesions which have a central vein in early
clinical presentations.
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connection with completing this licensing transaction, you agree that the following terms
and conditions apply to this transaction (along with the Billing and Payment terms and
conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you
opened your Rightslink account and that are available at any time at
http://myaccount.copyright.com).
GENERAL TERMS
2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to
the terms and conditions indicated.
3. Acknowledgement: If any part of the material to be used (for example, figures) has
appeared in our publication with credit or acknowledgement to another source, permission
must also be sought from that source. If such permission is not obtained then that material
may not be included in your publication/copies. Suitable acknowledgement to the source
must be made, either as a footnote or in a reference list at the end of your publication, as
follows:
“Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of
chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE
SOCIETY COPYRIGHT OWNER].” Also Lancet special credit - “Reprinted from The
Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with
permission from Elsevier.”
4. Reproduction of this material is confined to the purpose and/or media for which
permission is hereby given.
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be
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altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions
and/or any other alterations shall be made only with prior written authorization of Elsevier
Ltd. (Please contact Elsevier at permissions@elsevier.com)
6. If the permission fee for the requested use of our material is waived in this instance,
please be advised that your future requests for Elsevier materials may attract a fee.
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the
combination of (i) the license details provided by you and accepted in the course of this
licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment
terms and conditions.
8. License Contingent Upon Payment: While you may exercise the rights licensed
immediately upon issuance of the license at the end of the licensing process for the
transaction, provided that you have disclosed complete and accurate details of your proposed
use, no license is finally effective unless and until full payment is received from you (either
by publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions. If
full payment is not received on a timely basis, then any license preliminarily granted shall be
deemed automatically revoked and shall be void as if never granted. Further, in the event
that you breach any of these terms and conditions or any of CCC's Billing and Payment
terms and conditions, the license is automatically revoked and shall be void as if never
granted. Use of materials as described in a revoked license, as well as any use of the
materials beyond the scope of an unrevoked license, may constitute copyright infringement
and publisher reserves the right to take any and all action to protect its copyright in the
materials.
9. Warranties: Publisher makes no representations or warranties with respect to the licensed
material.
10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and
their respective officers, directors, employees and agents, from and against any and all
claims arising out of your use of the licensed material other than as specifically authorized
pursuant to this license.
11. No Transfer of License: This license is personal to you and may not be sublicensed,
assigned, or transferred by you to any other person without publisher's written permission.
12. No Amendment Except in Writing: This license may not be amended except in a writing
signed by both parties (or, in the case of publisher, by CCC on publisher's behalf).
13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any
purchase order, acknowledgment, check endorsement or other writing prepared by you,
which terms are inconsistent with these terms and conditions or CCC's Billing and Payment
terms and conditions. These terms and conditions, together with CCC's Billing and Payment
terms and conditions (which are incorporated herein), comprise the entire agreement
between you and publisher (and CCC) concerning this licensing transaction. In the event of
any conflict between your obligations established by these terms and conditions and those
established by CCC's Billing and Payment terms and conditions, these terms and conditions
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shall control.
14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described
in this License at their sole discretion, for any reason or no reason, with a full refund payable
to you. Notice of such denial will be made using the contact information provided by you.
Failure to receive such notice will not alter or invalidate the denial. In no event will Elsevier
or Copyright Clearance Center be responsible or liable for any costs, expenses or damage
incurred by you as a result of a denial of your permission request, other than a refund of the
amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied
permissions.
LIMITED LICENSE
The following terms and conditions apply only to specific license types:
15. Translation: This permission is granted for non-exclusive world English rights only
unless your license was granted for translation rights. If you licensed translation rights you
may only translate this content into the languages you requested. A professional translator
must perform all translations and reproduce the content word for word preserving the
integrity of the article. If this license is to re-use 1 or 2 figures then permission is granted for
non-exclusive world rights in all languages.
16. Website: The following terms and conditions apply to electronic reserve and author
websites:
Electronic reserve: If licensed material is to be posted to website, the web site is to be
password-protected and made available only to bona fide students registered on a relevant
course if:
This license was made in connection with a course,
This permission is granted for 1 year only. You may obtain a license for future website
posting,
All content posted to the web site must maintain the copyright information line on the
bottom of each image,
A hyper-text must be included to the Homepage of the journal from which you are licensing
at http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books
at http://www.elsevier.com , and
Central Storage: This license does not include permission for a scanned version of the
material to be stored in a central repository such as that provided by Heron/XanEdu.
17. Author website for journals with the following additional clauses:
All content posted to the web site must maintain the copyright information line on the
bottom of each image, and the permission granted is limited to the personal version of your
paper. You are not allowed to download and post the published electronic version of your
article (whether PDF or HTML, proof or final version), nor may you scan the printed edition
to create an electronic version. A hyper-text must be included to the Homepage of the
journal from which you are licensing at http://www.sciencedirect.com/science/journal/xxxxx
. As part of our normal production process, you will receive an e-mail notice when your
article appears on Elsevier’s online service ScienceDirect (www.sciencedirect.com). That ehttps://s100.copyright.com/CustomerAdmin/PLF.jsp?ref=9b530821-e904-4b92-b9b3-ef59d5d0bd1b
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mail will include the article’s Digital Object Identifier (DOI). This number provides the
electronic link to the published article and should be included in the posting of your personal
version. We ask that you wait until you receive this e-mail and have the DOI to do any
posting.
Central Storage: This license does not include permission for a scanned version of the
material to be stored in a central repository such as that provided by Heron/XanEdu.
18. Author website for books with the following additional clauses:
Authors are permitted to place a brief summary of their work online only.
A hyper-text must be included to the Elsevier homepage at http://www.elsevier.com . All
content posted to the web site must maintain the copyright information line on the bottom of
each image. You are not allowed to download and post the published electronic version of
your chapter, nor may you scan the printed edition to create an electronic version.
Central Storage: This license does not include permission for a scanned version of the
material to be stored in a central repository such as that provided by Heron/XanEdu.
19. Website (regular and for author): A hyper-text must be included to the Homepage of the
journal from which you are licensing at
http://www.sciencedirect.com/science/journal/xxxxx. or for books to the Elsevier homepage
at http://www.elsevier.com
20. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be
submitted to your institution in either print or electronic form. Should your thesis be
published commercially, please reapply for permission. These requirements include
permission for the Library and Archives of Canada to supply single copies, on demand, of
the complete thesis and include permission for UMI to supply single copies, on demand, of
the complete thesis. Should your thesis be published commercially, please reapply for
permission.
21. Other Conditions: Permission is granted to submit your article in print and electronic
format. This license permits you to post this Elsevier article online if it is embedded within
your thesis. You are also permitted to post your Author Accepted Manuscript online
however posting of the final published article is prohibited. Please refer to Elsevier’s Posting
Policy for further information:
http://www.elsevier.com/wps/find/authors.authors/postingpolicy

v1.6
If you would like to pay for this license now, please remit this license along with your
payment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise you will be
invoiced within 48 hours of the license date. Payment should be in the form of a check
or money order referencing your account number and this invoice number
RLNK501089925.
Once you receive your invoice for this order, you may pay your invoice by credit card.
Please follow instructions provided at that time.
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